RESULT_COUNT: 306,PAGE_SIZE: 10000,CURRENT_PAGE: 1,TOTAL_PAGES: 1,API_CALL_CREDITS: 1
TICKER,FIGI_TICKER,FIGI,TITLE,PUBLICATION_DATE,URL,SUMMARY
RARE,RARE:UW,BBG005KLVV24,See what the IHS Markit Score report has to say about Ultragenyx Pharmaceutical Inc.,2017-10-17 12:05:17 +0000,https://finance.yahoo.com/news/see-ihs-markit-score-report-120517992.html?.tsrc=rss,"The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices.  Index (PMI) data, output in the Healthcare sector is rising."
RARE,RARE:UW,BBG005KLVV24,See what the IHS Markit Score report has to say about Ultragenyx Pharmaceutical Inc.,2017-10-16 13:43:43 +0000,https://finance.yahoo.com/news/see-ihs-markit-score-report-134343695.html?.tsrc=rss,Ultragenyx Pharmaceutical Inc NASDAQ/NGS:RARE
RARE,RARE:UW,BBG005KLVV24,How Spark's Gene Therapy Win Could Also Be A Boon For These Biotechs,2017-10-13 22:16:34 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Es_cHrfg1D8/how-sparks-gene-therapy-win-could-also-be-a-boon-for-these-biotechs-cm859500,Spark Therapeutics ONCE positive vote by a Food and Drug Administration committee could be a boon for other drugmakers working on gene therapies including Audentes Therapeutics BOLD BioMarin Pharmaceutical BMRN and Ultragenyx
RARE,RARE:UW,BBG005KLVV24,How Spark&apos;s Gene Therapy Win Could Also Be A Boon For These Biotechs,2017-10-13 16:09:05 +0000,http://finance.yahoo.com/r/597ea164-2154-37fe-b395-0610fa76a9f5/how-sparks-gene-therapy-win-could-also-be-a-boon-for-these-biotechs?src=A00220&yptr=yahoo&.tsrc=rss,"Spark&apos;s positive vote by an FDA committee could be a boon for other drugmakers working on gene therapies including Audentes, BioMarin and Ultragenyx."
RARE,RARE:UW,BBG005KLVV24,"WEISSLAW LLP: Dimension Therapeutics, Inc. Acquisition May Not Be in the Best Interests of DMTX Shareholders",2017-10-13 15:18:00 +0000,https://finance.yahoo.com/news/weisslaw-llp-dimension-therapeutics-inc-151800477.html?.tsrc=rss,"NEW YORK , Oct. 13, 2017 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the Board of Directors of Dimension Therapeutics, Inc. (""DMTX"" ..."
RARE,RARE:UW,BBG005KLVV24,"CRY Opens Wallet, LLY's JUNIPER Flops, MDXG Catches Eyes, RNN Awaits DATA In Q4",2017-10-11 01:42:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/EzjObddRtQY/cry-opens-wallet-llys-juniper-flops-mdxg-catches-eyes-rnn-awaits-data-in-q4-20171011-00020,"CRY Opens Wallet, LLY's JUNIPER Flops, MDXG Catches Eyes, RNN Awaits DATA In Q4"
RARE,RARE:UW,BBG005KLVV24,Ultragenyx and Kyowa Hakko Kirin Announce FDA Acceptance and Priority Review Designation of Burosumab’s Biologics License Application,2017-10-10 12:30:00 +0000,https://finance.yahoo.com/news/ultragenyx-kyowa-hakko-kirin-announce-123000130.html?.tsrc=rss,"NOVATO, Calif., TOKYO and LONDON, Oct. 10, 2017-- Ultragenyx Pharmaceutical Inc., a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, Kyowa Hakko ..."
RARE,RARE:UW,BBG005KLVV24,"Ultragenyx Pharmaceutical, Inc. breached its 50 day moving average in a Bearish Manner : RARE-US : October 4, 2017",2017-10-04 12:27:50 +0000,http://finance.yahoo.com/r/59965011-3f97-357d-bfc2-d0033b3240a7/ultragenyx-pharmaceutical-inc-breached-its-50-day-moving-average-in-a-bearish-manner-rare-us-october-4-2017?yptr=yahoo&.tsrc=rss,"Categories:  ETFs Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Ultragenyx Pharmaceutical, Inc.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bearish Closing Price above/below 200 Day Moving Average Bearish ... Read more
<b>(Read more...)</b>"
RARE,RARE:UW,BBG005KLVV24,"​After bidding war, North Bay drug maker snags gene therapy company for $151 million",2017-10-03 18:35:09 +0000,http://finance.yahoo.com/r/df40f47f-e2c9-3fc6-8058-e452d4c7efee/ultragenyx-rare-dimension-dmtx-regenxbio-rgnx.html?ana=yahoo&yptr=yahoo&.tsrc=rss,"After weighing buyout offers from two biotechs, gene therapy company Dimension Therapeutics said Tuesday that it accepted the superior proposal — a $151 million deal from a North Bay company that will allow the company to maintain a New England presence.  Novato-based Ultragenyx Pharmaceutical (RARE) will buy Dimension (DMTX) for $6 per share.  ""I am thankful for the hard work and dedication of our talented employees, and am confident they will continue to make valuable contributions as part of a larger organization,"" Dimension CEO Annalisa Jenkins said in a statement."
RARE,RARE:UW,BBG005KLVV24,"​After bidding war, Cambridge gene therapy firm Dimension accepts $151M buyout",2017-10-03 16:20:10 +0000,http://finance.yahoo.com/r/c1d2dae4-a101-3aba-83f8-ed445ce56403/after-bidding-war-cambridge-gene-therapy-firm.html?ana=yahoo&yptr=yahoo&.tsrc=rss,"After weighing buyout offers from two out-of-state biotechs, Cambridge gene therapy firm Dimension Therapeutics said Tuesday that it has accepted the superior proposal — a $151 million deal that will allow the company to maintain a local presence.  Dimension (DMTX) said it had agreed to be acquired by California-based Ultragenyx Pharmaceutical (RARE) for $6 per share."
RARE,RARE:UW,BBG005KLVV24,Dimension Shares Rise On Sale to Ultragenyx - Biotech Movers,2017-10-03 13:58:00 +0000,http://finance.yahoo.com/r/9c098f10-db17-386c-8df5-f27d55ec3959/dimension-shares-rise-on-sale-to-ultragenyx-biotech-movers.html?puc=yahoo&cm_ven=YAHOO&yptr=yahoo&.tsrc=rss,Dimension Therapeutics said Oct. 3 it has agreed to sell to Ultragenyx Pharmaceutical for $6 a share in cash or about $151M.
RARE,RARE:UW,BBG005KLVV24,Ultragenyx to Acquire Dimension Therapeutics,2017-10-03 12:30:00 +0000,https://finance.yahoo.com/news/ultragenyx-acquire-dimension-therapeutics-123000613.html?.tsrc=rss,Ultragenyx Enters into Definitive Agreement to Acquire Dimension for $6.00 Per Share in Cash in a Transaction Valued at Approximately $151 Million Based on Currently Outstanding Shares. Combined Company ...
RARE,RARE:UW,BBG005KLVV24,Ultragenyx To Acquire Dimension Therapeutics In Approx. $151 Mln Deal,2017-10-03 08:41:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/MXtrGehUtlc/ultragenyx-to-acquire-dimension-therapeutics-in-approx-151-mln-deal-20171003-00599,Ultragenyx To Acquire Dimension Therapeutics In Approx. $151 Mln Deal
RARE,RARE:UW,BBG005KLVV24,"VICL Soars After-hours, DMTX Deems RARE Bid Superior, MDXG On Watch",2017-10-03 01:05:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Bw4ozm4q16o/vicl-soars-afterhours-dmtx-deems-rare-bid-superior-mdxg-on-watch-20171003-00026,"VICL Soars After-hours, DMTX Deems RARE Bid Superior, MDXG On Watch"
RARE,RARE:UW,BBG005KLVV24,RegenxBio declines to push forward on planned acquisition,2017-10-02 18:25:08 +0000,http://finance.yahoo.com/r/50cb1716-7859-3500-bb5a-e850e935ec57/regenxbio-declines-to-push-forward-on-planned.html?ana=yahoo&yptr=yahoo&.tsrc=rss,"Rockville-based RegenxBio Inc. has opted to back away from a deal to buy Dimension Therapeutics Inc. (DMTX) after the Boston-area biotech received a better buyout offer.  RegenxBio (RGNX) said Monday morning it doesn't plan to match, or best, the unsolicited $6-per-share price that Ultragenyx Pharmaceutical (RARE), based in Novato, California, is now offering to Dimension Therapeutics, a Cambridge, Massachusetts, biotech that's struggled with its pipeline in the last year.  In August, RegenxBio announced plans to buy Dimension in an all-stock transaction that valued the deal at $3.41 per share, or $86 million in all."
RARE,RARE:UW,BBG005KLVV24,REGENXBIO Responds to Notification of a Superior Proposal Under Its Merger Agreement With Dimension Therapeutics,2017-10-02 12:30:00 +0000,https://finance.yahoo.com/news/regenxbio-responds-notification-superior-proposal-123000678.html?.tsrc=rss,"ROCKVILLE, Md., Oct. 02, 2017-- REGENXBIO Inc. today announced that Dimension Therapeutics, Inc. notified REGENXBIO that it has determined that it has received a“ superior proposal” as defined in the merger ..."
RARE,RARE:UW,BBG005KLVV24,See what the IHS Markit Score report has to say about Ultragenyx Pharmaceutical Inc.,2017-10-02 12:02:34 +0000,https://finance.yahoo.com/news/see-ihs-markit-score-report-120234565.html?.tsrc=rss,Ultragenyx Pharmaceutical Inc NASDAQ/NGS:RARE
RARE,RARE:UW,BBG005KLVV24,Dimension Board Determines that Ultragenyx’s Unsolicited Proposal to Acquire Dimension for $6.00 Per Share Constitutes a “Superior Proposal”,2017-10-02 12:00:00 +0000,https://finance.yahoo.com/news/dimension-board-determines-ultragenyx-unsolicited-120000716.html?.tsrc=rss,"CAMBRIDGE, Mass., Oct. 02, 2017-- Dimension Therapeutics, Inc. announced today that the Dimension Board of Directors has determined that an unsolicited proposal received from Ultragenyx Pharmaceutical ..."
RARE,RARE:UW,BBG005KLVV24,Gene Therapy: A Big Week for Many Names,2017-09-25 14:47:41 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/cdGvwJIxtoE/gene-therapy-a-big-week-for-many-names-cm850359,It s been a big week for the gene therapy universe It s been a big week for the gene therapy universe Of course there s the latest Barron s cover story which details the emerging medical revolution and highlights three stocks AveXis AVXS Regenxbio RGNX and Spark
RARE,RARE:UW,BBG005KLVV24,Gene Therapy: A Big Week for Many Names,2017-09-25 13:57:00 +0000,http://finance.yahoo.com/r/d83c2532-8e77-327e-a958-c7fa98ebcf0a/gene-therapy-a-big-week-for-many-names-1506347828?mod=yahoobarrons&ru=yahoo&yptr=yahoo&.tsrc=rss,"It’s been a big week for the gene therapy universe.  Of course, there’s the latest Barron’s  cover story, which details the emerging medical revolution and highlights three stocks -- AveXis (AVXS), Regenxbio (RGNX), and Spark Therapeutics (ONCE) -- that have big stakes in what is widely considered one of the most exciting areas in the biotechnology arena.  Last week, Ultragenyx Pharmaceutical (RARE) offered to buy  Dimension Therapeutics (DMTX) for at $5.50 per share in cash."
RARE,RARE:UW,BBG005KLVV24,Dimension Board of Directors Determines Proposal from Ultragenyx Pharmaceutical Inc. Could Reasonably Be Expected to Lead to a “Superior Proposal”,2017-09-19 12:00:00 +0000,https://finance.yahoo.com/news/dimension-board-directors-determines-proposal-120000104.html?.tsrc=rss,"CAMBRIDGE, Mass., Sept. 19, 2017-- Dimension Therapeutics, Inc., a leader in discovering and developing new therapeutic products for people living with devastating rare and metabolic diseases associated ..."
RARE,RARE:UW,BBG005KLVV24,"NBRV Leaps On Study Data, CSII Takes A Hit, CLVS Abuzz, New Dimension For DMTX",2017-09-18 23:09:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/JFcEx12x7zc/nbrv-leaps-on-study-data-csii-takes-a-hit-clvs-abuzz-new-dimension-for-dmtx-20170918-01351,"NBRV Leaps On Study Data, CSII Takes A Hit, CLVS Abuzz, New Dimension For DMTX"
RARE,RARE:UW,BBG005KLVV24,Dimension Confirms Receipt of Unsolicited Proposal from Ultragenyx,2017-09-18 19:10:00 +0000,https://finance.yahoo.com/news/dimension-confirms-receipt-unsolicited-proposal-191000184.html?.tsrc=rss,"CAMBRIDGE, Mass., Sept. 18, 2017-- Dimension Therapeutics, Inc., a leader in discovering and developing new therapeutic products for people living with devastating rare and metabolic diseases associated ..."
RARE,RARE:UW,BBG005KLVV24,UPDATED: Dimension Therapeutics shares surge 38% on Ultragenyx bid,2017-09-18 17:18:05 +0000,http://finance.yahoo.com/r/9c97cae8-2b06-3333-929e-1825a2b1925b/Story.aspx?guid=F98523B8-1534-4049-AB93-53A4BF5B4A6B&siteid=yhoof2&yptr=yahoo&.tsrc=rss,"Dimension Therapeutics Inc. shares surged 38% in early afternoon trade Monday on news that Ultragenyx Pharmaceutical Inc. has proposed to buy all its outstanding common stock for $5.50 per share, or about ..."
RARE,RARE:UW,BBG005KLVV24,Health Care Sector Update for 09/18/2017: DMTX,2017-09-18 13:36:55 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/LSRbTuCtgwg/health-care-sector-update-for-09182017-dmtx-cm846952,Top Health care stocks Top Health care stocks JNJ 0 4 JNJ 0 4 PFE flatPFE flat ABT flatABT flat MRK 0 2 MRK 0 2 AMGN 0 3 AMGN 0 3 Health care shares were mixed in pre market trade Monday Health care shares were mixed in pre market trade Monday In health care stocks
RARE,RARE:UW,BBG005KLVV24,Ultragenyx Makes Bid for Dimension Therapeutics - Biotech Movers,2017-09-18 13:35:00 +0000,http://finance.yahoo.com/r/2e8caab2-4cfc-3942-9d8c-4cdf075109ee/ultragenyx-makes-bid-for-dimension-therapeutics.html?puc=yahoo&cm_ven=YAHOO&yptr=yahoo&.tsrc=rss,"Ultragenyx Pharmaceutical made a proposal to acquire Dimension Therapeutics, which last month agreed to sell to Regenxbio."
RARE,RARE:UW,BBG005KLVV24,Ultragenyx Proposes to Acquire Dimension Therapeutics for $5.50 Per Share in Cash,2017-09-18 12:35:00 +0000,https://finance.yahoo.com/news/ultragenyx-proposes-acquire-dimension-therapeutics-123500484.html?.tsrc=rss,Proposed Combination of Complementary Rare Disease Franchises Maximizes the Ability to Bring Needed New Therapies to Market. Proposal Delivers Superior Value To Dimension’ s Shareholders Relative to the ...
RARE,RARE:UW,BBG005KLVV24,Ultragenyx Proposes To Buy Dimension Therapeutics For $5.50/shr In Cash,2017-09-18 08:43:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/OBZ1dj6b-W0/ultragenyx-proposes-to-buy-dimension-therapeutics-for-550shr-in-cash-20170918-00599,Ultragenyx Proposes To Buy Dimension Therapeutics For $5.50/shr In Cash
RARE,RARE:UW,BBG005KLVV24,Today's Research Reports on Trending Tickers: bluebird bio and Ultragenyx Pharmaceutical,2017-09-15 12:00:00 +0000,https://finance.yahoo.com/news/todays-research-reports-trending-tickers-120000124.html?.tsrc=rss,"NEW YORK, NY / ACCESSWIRE / September 15, 2017 / The Dow Jones Industrial Average closed at a new record high for the third consecutive session on the strength of Boeing and United Technologies, while ..."
RARE,RARE:UW,BBG005KLVV24,Ultragenyx's Burosumab Positive in Phase II for XLH and TIO,2017-09-12 16:39:28 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Cq6lhiUvjSg/ultragenyxs-burosumab-positive-in-phase-ii-for-xlh-and-tio-cm844428,Ultragenyx Pharmaceutical Inc RARE announced positive data from two phase II studies evaluating pipeline candidate burosumab KRN23 in children with X linked hypophosphatemia XLH and adult with tumor induced osteomalacia TIO Data from the studies were presented at the American Society
RARE,RARE:UW,BBG005KLVV24,Ultragenyx&apos;s Burosumab Positive in Phase II for XLH and TIO,2017-09-12 14:31:02 +0000,https://finance.yahoo.com/news/ultragenyx-apos-burosumab-positive-phase-143102832.html?.tsrc=rss,Ultragenyx&apos;s (RARE) burosumab passes the test with positive data from two phase II studies. The candidate gets evaluated for X-linked hypophosphatemia and tumor-induced osteomalacia.
RARE,RARE:UW,BBG005KLVV24,"Keep Close Watch On ALDX Today, ABBV Just Hit Another High, Fennec Uplisted",2017-09-12 02:47:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/2ukkrom-ueg/keep-close-watch-on-aldx-today-abbv-just-hit-another-high-fennec-uplisted-20170912-00079,"Keep Close Watch On ALDX Today, ABBV Just Hit Another High, Fennec Uplisted"
RARE,RARE:UW,BBG005KLVV24,Ultragenyx and Kyowa Hakko Kirin Announce Additional Burosumab Data in X-Linked Hypophosphatemia (XLH) and Tumor-Induced Osteomalacia (TIO) at ASBMR,2017-09-11 19:00:00 +0000,https://finance.yahoo.com/news/ultragenyx-kyowa-hakko-kirin-announce-190000805.html?.tsrc=rss,"NOVATO, Calif. and TOKYO, Sept. 11, 2017-- Ultragenyx Pharmaceutical Inc., a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, and Kyowa Hakko Kirin ..."
RARE,RARE:UW,BBG005KLVV24,See what the IHS Markit Score report has to say about Ultragenyx Pharmaceutical Inc.,2017-09-11 14:09:19 +0000,https://finance.yahoo.com/news/see-ihs-markit-score-report-140919827.html?.tsrc=rss,Ultragenyx Pharmaceutical Inc NASDAQ/NGS:RARE
RARE,RARE:UW,BBG005KLVV24,See what the IHS Markit Score report has to say about Ultragenyx Pharmaceutical Inc.,2017-09-08 14:25:10 +0000,https://finance.yahoo.com/news/see-ihs-markit-score-report-142510049.html?.tsrc=rss,Ultragenyx Pharmaceutical Inc NASDAQ/NGS:RARE
RARE,RARE:UW,BBG005KLVV24,Ultragenyx to Present at the Morgan Stanley Global Healthcare Conference,2017-09-06 12:30:00 +0000,https://finance.yahoo.com/news/ultragenyx-present-morgan-stanley-global-123000385.html?.tsrc=rss,"NOVATO, Calif., Sept. 06, 2017-- Ultragenyx Pharmaceutical Inc., a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced that Shalini ..."
RARE,RARE:UW,BBG005KLVV24,See what the IHS Markit Score report has to say about Ultragenyx Pharmaceutical Inc.,2017-09-06 12:05:02 +0000,https://finance.yahoo.com/news/see-ihs-markit-score-report-120502152.html?.tsrc=rss,Ultragenyx Pharmaceutical Inc NASDAQ/NGS:RARE
RARE,RARE:UW,BBG005KLVV24,Analysts Predict 12% Gains Ahead For FBT,2017-08-31 13:52:40 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/gbtwCgGAZMI/analysts-predict-12-gains-ahead-for-fbt-cm839559,Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel we have compared the trading price of each holding against the average analyst 12 month forward target price and computed the weighted average implied analyst target price for the ETF itself For the
RARE,RARE:UW,BBG005KLVV24,Ultragenyx to Present at the Baird 2017 Global Healthcare Conference,2017-08-31 12:30:00 +0000,https://finance.yahoo.com/news/ultragenyx-present-baird-2017-global-123000895.html?.tsrc=rss,"NOVATO, Calif., Aug. 31, 2017-- Ultragenyx Pharmaceutical Inc., a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced that Emil Kakkis, ..."
RARE,RARE:UW,BBG005KLVV24,"Wednesday 8/30 Insider Buying Report: RARE, RGC",2017-08-30 15:49:56 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/hjOmIrkkeLw/wednesday-830-insider-buying-report-rare-rgc-cm839142,As the saying goes there are many possible reasons for an insider to sell a stock but only one reason to buy they expect to make money So let s look at two noteworthy recent insider buys On Monday Ultragenyx Pharmaceutical s CEO Emil D Kakkis made a 393 922 buy of RARE
RARE,RARE:UW,BBG005KLVV24,Ultragenyx Files BLA to FDA for Hypophosphatemia Candidate,2017-08-25 16:44:49 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Pl660jolxgo/ultragenyx-files-bla-to-fda-for-hypophosphatemia-candidate-cm837231,Ultragenyx Pharmaceutical Inc RARE along with Japanese partner Kyowa Hakko Kirin Co Ltd announced filing of a biologics license application BLA to the FDA for its pipeline candidate burosumab KRN23 to treat patients with X linked hypophosphatemia XLH The FDA informed that a decision
RARE,RARE:UW,BBG005KLVV24,Ultragenyx Files BLA to FDA for Hypophosphatemia Candidate,2017-08-25 14:23:02 +0000,https://finance.yahoo.com/news/ultragenyx-files-bla-fda-hypophosphatemia-142302575.html?.tsrc=rss,Ultragenyx (RARE) forwards a BLA to the FDA for burosumab with a view to treat patients with X-linked hypophosphatemia (XLH). The decision on acceptance will be known within a couple of months.
RARE,RARE:UW,BBG005KLVV24,Ultragenyx and Kyowa Hakko Kirin Announce Submission of Burosumab’s Biologics License Application in the US,2017-08-24 12:30:00 +0000,https://finance.yahoo.com/news/ultragenyx-kyowa-hakko-kirin-announce-123000861.html?.tsrc=rss,"NOVATO, Calif. and TOKYO, Aug. 24, 2017-- Ultragenyx Pharmaceutical Inc., a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, and Kyowa Hakko Kirin ..."
RARE,RARE:UW,BBG005KLVV24,Ultragenyx Announces Burosumab Data Presentations at ASBMR 2017 Annual Meeting,2017-08-24 12:30:00 +0000,https://finance.yahoo.com/news/ultragenyx-announces-burosumab-data-presentations-123000211.html?.tsrc=rss,"NOVATO, Calif., Aug. 24, 2017-- Ultragenyx Pharmaceutical Inc., a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced upcoming presentations ..."
RARE,RARE:UW,BBG005KLVV24,Today's Research Reports on Stocks to Watch: Paratek Pharmaceuticals Inc. and Ultragenyx Pharmaceutical Inc.,2017-08-24 12:10:00 +0000,https://finance.yahoo.com/news/todays-research-reports-stocks-watch-121000002.html?.tsrc=rss,"NEW YORK, NY / ACCESSWIRE / August 24, 2017 / Negative results from Ultragenyx's Ace-ER phase III study sent shares deep into the red on Wednesday with the company even announcing that it plans to discontinue ..."
RARE,RARE:UW,BBG005KLVV24,See what the IHS Markit Score report has to say about Ultragenyx Pharmaceutical Inc.,2017-08-24 12:02:23 +0000,https://finance.yahoo.com/news/see-ihs-markit-score-report-120223943.html?.tsrc=rss,Ultragenyx Pharmaceutical Inc NASDAQ/NGS:RARE
RARE,RARE:UW,BBG005KLVV24,Ultragenyx (RARE) Posts Disappointing Phase III Ace-ER Data,2017-08-23 22:38:21 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Q8SuS9Vcn5M/ultragenyx-rare-posts-disappointing-phase-iii-ace-er-data-cm836242,Ultragenyx Pharmaceutical Inc RARE announced discouraging top line data from a phase III study evaluating its investigational Ace ER aceneuramic acid extended release on patients with GNE Myopathy GNEM a progressive muscle wasting disorder As a result the company plans to discontinue
RARE,RARE:UW,BBG005KLVV24,"Why Stryker, Ultragenyx Pharmaceutical, and La-Z-Boy Slumped Today",2017-08-23 22:37:33 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/zUfz1AaBnbA/why-stryker-ultragenyx-pharmaceutical-and-la-z-boy-slumped-today-cm836234,Major benchmarks trended downward Wednesday taking a break from the rally that had boosted stocks in the previous session Investors seemed uncertain about President Donald Trump s plans to abandon the North American Free Trade Agreement NAFTA Among the worst performers of the day
RARE,RARE:UW,BBG005KLVV24,"Gainers & Losers Of Aug.23: ITCI, PRTK, MBIO, RARE, OVID...",2017-08-23 22:09:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/He-3ePTEzdI/gainers--losers-of-aug23-itci-prtk-mbio-rare-ovid-20170823-01112,"Gainers & Losers Of Aug.23: ITCI, PRTK, MBIO, RARE, OVID..."
RARE,RARE:UW,BBG005KLVV24,Why Ultragenyx Pharmaceutical Stock Is Sinking Today,2017-08-23 21:38:38 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/zecYc2UJ7iQ/why-ultragenyx-pharmaceutical-stock-is-sinking-today-cm836223,What happened Shares of the rare disease drugmaker Ultragenyx Pharmaceutical NASDAQ RARE are under pressure today after the company announced that its late stage study assessing aceneuramic acid extended release Ace ER in patients with the genetically inherited muscle
RARE,RARE:UW,BBG005KLVV24,Ultragenyx Pharmaceutical is Now Oversold (RARE),2017-08-23 21:37:24 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/rdp6jcmWjlk/ultragenyx-pharmaceutical-is-now-oversold-rare-cm836212,Legendary investor Warren Buffett advises to be fearful when others are greedy and be greedy when others are fearful One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index or RSI which measures momentum on
RARE,RARE:UW,BBG005KLVV24,"Why Stryker, Ultragenyx Pharmaceutical, and La-Z-Boy Slumped Today",2017-08-23 21:15:00 +0000,http://finance.yahoo.com/r/6041b465-1b7d-34be-9c7d-e8dcf417e055/why-stryker-ultragenyx-la-z-boy-slumped-today.aspx?yptr=yahoo&.tsrc=rss,These stocks helped put downward pressure on the market. Find out why.
RARE,RARE:UW,BBG005KLVV24,"Why Omnicom Group Inc. (OMC), Ultragenyx Pharmaceutical Inc (RARE) and Stryker Corporation (SYK) Are 3 of Today’s Worst Stocks",2017-08-23 20:31:35 +0000,https://finance.yahoo.com/news/why-omnicom-group-inc-omc-203135878.html?.tsrc=rss,"For the third quarter currently underway, Stryker expects earnings to roll in between $1.50 and $1.55 per share of SYK, versus analyst estimates of $1.53.  At the same time, Stryker announced it was recalling certain Oral Care products and it was simultaneously, temporarily holding shipments of some cloth-based products.  Advertising and public relations outfit Omnicom Group was Tuesday’s biggest large-cap loser, but not because of anything Omnicom specifically did."
RARE,RARE:UW,BBG005KLVV24,Ultragenyx (RARE) Posts Disappointing Phase III Ace-ER Data,2017-08-23 20:06:08 +0000,https://finance.yahoo.com/news/ultragenyx-rare-posts-disappointing-phase-200608109.html?.tsrc=rss,Ultragenyx (RARE) plans to discontinue further clinical development of Ace-ER after posting discouraging data from a phase III study that evaluated the candidate on patients with GNE Myopathy.
RARE,RARE:UW,BBG005KLVV24,Why Ultragenyx Pharmaceutical Stock Is Sinking Today,2017-08-23 19:37:00 +0000,http://finance.yahoo.com/r/3a9dc70b-86af-3c31-bb06-d8d7d98536fa/why-ultragenyx-pharmaceutical-stock-is-sinking-tod.aspx?yptr=yahoo&.tsrc=rss,Ultragenyx&apos;s shares are reeling after the company&apos;s experimental drug for muscle-wasting disease fails in a late-stage study.
RARE,RARE:UW,BBG005KLVV24,"Health Care Sector Update for 08/23/2017: RARE,ITCI,PRPO",2017-08-23 18:57:56 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/f_r7prfVOcM/health-care-sector-update-for-08232017-rareitciprpo-cm836140,Top Health Care StocksTop Health Care Stocks JNJ 1 31 JNJ 1 31 PFE 0 47 PFE 0 47 ABT 0 32 ABT 0 32 MRK 0 24 MRK 0 24 AMGN 0 65 AMGN 0 65 Health care stocks continue to struggle in recent trading with the NYSE Health Care Index sinking almost 0 7 while shares of health
RARE,RARE:UW,BBG005KLVV24,Ultragenyx Discontinues Phase 3 GNE Myopathy Study,2017-08-23 15:22:04 +0000,https://finance.yahoo.com/news/ultragenyx-discontinues-phase-3-gne-152204277.html?.tsrc=rss,Shares of Ultragenyx Pharmaceutical Inc (NASDAQ: RARE ) tumbled more than 12 percent Wednesday after the company offered a disappointing update concerning a muscle-disease drug study. The biopharmaceutical ...
RARE,RARE:UW,BBG005KLVV24,Ultragenyx Stumbles Over Late-Stage Trial,2017-08-23 14:30:54 +0000,https://finance.yahoo.com/news/ultragenyx-stumbles-over-stage-trial-143154227.html?.tsrc=rss,Ultragenyx Pharmaceutical shares took a turn for the worse on Wednesday after a report that results from its late-stage trial did not live up to expectations.
RARE,RARE:UW,BBG005KLVV24,"Biotech Stock Roundup: EU Label Expansion for Alexion, BIIB Facing Drug Price Probe",2017-08-23 11:56:11 +0000,https://finance.yahoo.com/news/biotech-stock-roundup-eu-label-115611574.html?.tsrc=rss,Key highlights include regulatory approvals for companies like Alexion (ALXN) and Ironwood while Biogen is one of the companies facing an investigation into the pricing of multiple sclerosis drugs.
RARE,RARE:UW,BBG005KLVV24,"RARE Disappoints, NSPR Put On Notice, PMD Launches Synthetic Cannabinoids Test",2017-08-23 02:01:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/so04Uv9d6Uo/rare-disappoints-nspr-put-on-notice-pmd-launches-synthetic-cannabinoids-test-20170823-00047,"RARE Disappoints, NSPR Put On Notice, PMD Launches Synthetic Cannabinoids Test"
RARE,RARE:UW,BBG005KLVV24,"Ultragenyx Pharmaceutical&apos;s Ace-ER trial misses the mark, shares crash",2017-08-22 23:50:00 +0000,https://finance.yahoo.com/news/ultragenyx-pharmaceutical-apos-ace-er-235000871.html?.tsrc=rss,Investing.com - Shares of Ultragenyx (NASDAQ:RARE). fell during Tuesday&apos;s after hours session in reaction to the company&apos;s report that a late-stage clinical trial for its severe muscle disease treatment failed to meet its primary endpoint.
RARE,RARE:UW,BBG005KLVV24,Ultragenyx shares drop as muscle-disease drug study fails,2017-08-22 20:49:26 +0000,http://finance.yahoo.com/r/a0fd08c7-5652-383c-b851-0fc83111818c/Story.aspx?guid=66F5AD0D-2E63-4198-804E-7CCBA93D6F6E&siteid=yhoof2&yptr=yahoo&.tsrc=rss,Ultragenyx Pharmaceutical Inc. shares fell in the extended session Tuesday after the biotech company said a late-stage clinical trial for its severe muscle disease treatment did not reach its goals. Shares ...
RARE,RARE:UW,BBG005KLVV24,Ultragenyx Announces Top-Line Results from Phase 3 Study of Ace-ER in GNE Myopathy,2017-08-22 20:05:00 +0000,https://finance.yahoo.com/news/ultragenyx-announces-top-line-results-200500792.html?.tsrc=rss,"NOVATO, Calif., Aug. 22, 2017-- Ultragenyx Pharmaceutical Inc., a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced that a Phase 3 ..."
RARE,RARE:UW,BBG005KLVV24,See what the IHS Markit Score report has to say about Ultragenyx Pharmaceutical Inc.,2017-08-21 12:02:30 +0000,https://finance.yahoo.com/news/see-ihs-markit-score-report-120230625.html?.tsrc=rss,Ultragenyx Pharmaceutical Inc NASDAQ/NGS:RARE
RARE,RARE:UW,BBG005KLVV24,"Ultragenyx Pharmaceutical, Inc. – Value Analysis (NASDAQ:RARE) : August 17, 2017",2017-08-17 02:08:02 +0000,http://finance.yahoo.com/r/634225d6-8a1f-3323-8e80-9db605ca4bb8/ultragenyx-pharmaceutical-inc-value-analysis-nasdaqrare-august-17-2017?yptr=yahoo&.tsrc=rss,"Categories:  Fundamental Analysis Yahoo FinanceClick here to see latest analysis Capitalcube gives Ultragenyx Pharmaceutical, Inc. a score of 38. Our analysis is based on comparing Ultragenyx Pharmaceutical, Inc. with the following peers – BioMarin Pharmaceutical Inc., Amicus Therapeutics, Inc., Esperion Therapeutics, Inc., Versartis, Inc., Alexion Pharmaceuticals, Inc., Albireo Pharma, Inc., Lexicon Pharmaceuticals, Inc. and Spherix Incorporated (BMRN-US, FOLD-US, ESPR-US, ... Read more
<b>(Read more...)</b>"
RARE,RARE:UW,BBG005KLVV24,Edited Transcript of RARE earnings conference call or presentation 27-Jul-17 9:00pm GMT,2017-08-12 11:00:55 +0000,https://finance.yahoo.com/news/edited-transcript-rare-earnings-conference-092335894.html?.tsrc=rss,Q2 2017 Ultragenyx Pharmaceutical Inc Earnings Call
RARE,RARE:UW,BBG005KLVV24,IHS Markit Score Update: Drop in demand for ETFs holding Ultragenyx Pharmaceutical Inc is a negative sign for its shares,2017-08-10 12:02:26 +0000,https://finance.yahoo.com/news/ihs-markit-score-drop-demand-120226734.html?.tsrc=rss,"The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices.  Index (PMI) data, output in the Healthcare sector is rising."
RARE,RARE:UW,BBG005KLVV24,"Ultragenyx Pharmaceutical, Inc. breached its 50 day moving average in a Bearish Manner : RARE-US : August 3, 2017",2017-08-03 13:49:52 +0000,http://finance.yahoo.com/r/3a59df13-0abb-30fc-9ced-8be32daaf1b7/ultragenyx-pharmaceutical-inc-breached-its-50-day-moving-average-in-a-bearish-manner-rare-us-august-3-2017?yptr=yahoo&.tsrc=rss,"Categories:  ETFs Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Ultragenyx Pharmaceutical, Inc.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bearish Closing Price above/below 200 Day Moving Average Bearish ... Read more
<b>(Read more...)</b>"
RARE,RARE:UW,BBG005KLVV24,Ultragenyx reports 2Q loss,2017-07-29 00:05:09 +0000,https://finance.yahoo.com/news/ultragenyx-reports-2q-loss-090333969.html?.tsrc=rss,"The Novato, California-based company said it had a loss of $1.72 per share. The results surpassed Wall Street expectations. The average estimate of 11 analysts surveyed by Zacks Investment Research was ..."
RARE,RARE:UW,BBG005KLVV24,"AGRX At FDA Altar Again, AZN Falls As MYSTIC Fails, VBIV Delivers A Good Shot",2017-07-28 00:57:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/M1dJplSycUc/agrx-at-fda-altar-again-azn-falls-as-mystic-fails-vbiv-delivers-a-good-shot-20170728-00011,"AGRX At FDA Altar Again, AZN Falls As MYSTIC Fails, VBIV Delivers A Good Shot"
RARE,RARE:UW,BBG005KLVV24,Ultragenyx Reports Second Quarter 2017 Financial Results and Corporate Update,2017-07-27 20:05:00 +0000,https://finance.yahoo.com/news/ultragenyx-reports-second-quarter-2017-200500097.html?.tsrc=rss,"NOVATO, Calif., July 27, 2017-- Ultragenyx Pharmaceutical Inc., a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today reported its financial results ..."
RARE,RARE:UW,BBG005KLVV24,Ultragenyx Pharmaceutical (RARE) Shares Cross Above 200 DMA,2017-07-17 16:48:22 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/iM4j8BtUlWY/ultragenyx-pharmaceutical-rare-shares-cross-above-200-dma-cm816952,In trading on Monday shares of Ultragenyx Pharmaceutical Inc Symbol RARE crossed above their 200 day moving average of 68 88 changing hands as high as 69 74 per share Ultragenyx Pharmaceutical Inc shares are currently trading up about 7 5 on the day The chart below shows the one
RARE,RARE:UW,BBG005KLVV24,"Notable Monday Option Activity: ICON, FB, RARE",2017-07-17 16:46:13 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/wuFq-Vr6kTo/notable-monday-option-activity-icon-fb-rare-cm816965,Among the underlying components of the Russell 3000 index we saw noteworthy options trading volume today in Iconix Brand Group Inc Symbol ICON where a total of 3 011 contracts have traded so far representing approximately 301 100 underlying shares That amounts to about 65 of ICON
RARE,RARE:UW,BBG005KLVV24,FBT's Underlying Holdings Could Mean 11% Gain Potential,2017-06-28 13:49:48 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/iExPAbG1c_8/fbts-underlying-holdings-could-mean-11-gain-potential-cm809205,Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel we have compared the trading price of each holding against the average analyst 12 month forward target price and computed the weighted average implied analyst target price for the ETF itself For the
RARE,RARE:UW,BBG005KLVV24,Seattle Genetics: A Disappointing Study…Or Was It?,2017-06-26 18:52:00 +0000,http://finance.yahoo.com/r/6af3866f-8299-3e70-b1cc-b4d07210c8ee/seattle-genetics-a-disappointing-studyor-was-it-1498503146?mod=yahoobarrons&ru=yahoo&yptr=yahoo&.tsrc=rss,"Shares of Seattle Genetics (SGEN) are moving lower today, falling more than 9% after the drug maker’s experimental lymphoma drug failed to impress.  The data from the late-stage study testing Adcetris, co-developed with Japan's Takeda Pharmaceutical, helped blood cancer patients live longer without worsening their conditions, meeting its endpoint.  Altogether, lots of uncertainty whether these data could support a robust commercial adoption."
RARE,RARE:UW,BBG005KLVV24,Ultragenyx Provides Regulatory Update on Burosumab (KRN23),2017-06-23 12:30:00 +0000,https://finance.yahoo.com/news/ultragenyx-provides-regulatory-burosumab-krn23-123000558.html?.tsrc=rss,"NOVATO, Calif., June 23, 2017-- Ultragenyx Pharmaceutical Inc., a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced that it has reached ..."
RARE,RARE:UW,BBG005KLVV24,"Oh, baby: How expanded newborn screening could change the face of health care",2017-06-21 20:38:56 +0000,http://finance.yahoo.com/r/bb39ed77-b0c6-350f-89cb-ab9207f2bcf3/newborn-screening-everylife-foundation-rare.html?ana=yahoo&yptr=yahoo&.tsrc=rss,"If a child isn't properly screened and diagnosed, it sometimes can cut years off the ability to pinpoint and treat a rare, progressive disease, for example.  The system for newborn screening comes with federal recommendations, but it's left to states to decide which tests they require.  Therein lies the rub: Newborn screening laws are slowly changing, state by state, but there are all sorts of political concerns, not the least of which is state budgets, says Max Bronstein, the chief advocacy and science policy officer at the EveryLife Foundation for Rare Diseases."
RARE,RARE:UW,BBG005KLVV24,"Ultragenyx Pharmaceutical, Inc. – Value Analysis (NASDAQ:RARE) : June 16, 2017",2017-06-16 21:01:43 +0000,http://finance.yahoo.com/r/5faa26c8-d594-303f-b4e1-36e34e810b20/ultragenyx-pharmaceutical-inc-value-analysis-nasdaqrare-june-16-2017?yptr=yahoo&.tsrc=rss,"Categories:  Fundamental Analysis Yahoo FinanceClick here to see latest analysis Capitalcube gives Ultragenyx Pharmaceutical, Inc. a score of 38. Our analysis is based on comparing Ultragenyx Pharmaceutical, Inc. with the following peers – BioMarin Pharmaceutical Inc., Amicus Therapeutics, Inc., Esperion Therapeutics, Inc., Versartis, Inc., Alexion Pharmaceuticals, Inc., Albireo Pharma, Inc., Lexicon Pharmaceuticals, Inc. and Spherix Incorporated (BMRN-US, FOLD-US, ESPR-US, ... Read more
<b>(Read more...)</b>"
RARE,RARE:UW,BBG005KLVV24,"Ultragenyx Pharmaceutical, Inc. breached its 50 day moving average in a Bullish Manner : RARE-US : June 15, 2017",2017-06-15 12:12:50 +0000,http://finance.yahoo.com/r/6629a894-c07f-3e59-978e-c416b7947712/ultragenyx-pharmaceutical-inc-breached-its-50-day-moving-average-in-a-bullish-manner-rare-us-june-15-2017?yptr=yahoo&.tsrc=rss,"Categories:  ETFs Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Ultragenyx Pharmaceutical, Inc.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bullish Closing Price above/below 200 Day Moving Average Bearish ... Read more
<b>(Read more...)</b>"
RARE,RARE:UW,BBG005KLVV24,Apple Could Explode Higher to $200 a Share If This Chart Pattern Is Correct,2017-06-09 17:19:00 +0000,http://finance.yahoo.com/r/b10e95aa-fbb3-3685-928e-c858930e98cc/apple-could-hit-200-fast-if-this-breakout-setup-triggers.html?puc=yahoo&cm_ven=YAHOO&yptr=yahoo&.tsrc=rss,Huge profits could be on the doorstep for these hot breakout setups.
RARE,RARE:UW,BBG005KLVV24,Ultragenyx to Present at Goldman Sachs 38th Annual Global Healthcare Conference,2017-06-07 12:30:00 +0000,https://finance.yahoo.com/news/ultragenyx-present-goldman-sachs-38th-123000451.html?.tsrc=rss,"NOVATO, Calif., June 07, 2017-- Ultragenyx Pharmaceutical Inc., a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced that Emil Kakkis, ..."
RARE,RARE:UW,BBG005KLVV24,Ultragenyx to Present at Jefferies Global Healthcare Conference,2017-06-01 12:30:00 +0000,https://finance.yahoo.com/news/ultragenyx-present-jefferies-global-healthcare-123000623.html?.tsrc=rss,"NOVATO, Calif., June 01, 2017-- Ultragenyx Pharmaceutical Inc., a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced that Shalini Sharp, ..."
RARE,RARE:UW,BBG005KLVV24,Ultragenyx Receives Priority Review for rhGUS from FDA,2017-05-24 14:35:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/kF8pl1tlk8M/ultragenyx-receives-priority-review-for-rhgus-from-fda-cm793872,Ultragenyx Pharmaceutical Inc RARE recently announced that it has submitted regulatory applications in both the U S and the EU for recombinant human beta glucuronidase rhGUS This is an investigational candidate that is being developed for the treatment of mucopolysaccharidosis VII MPS
RARE,RARE:UW,BBG005KLVV24,Ultragenyx Receives Priority Review for rhGUS from FDA,2017-05-24 13:17:01 +0000,https://finance.yahoo.com/news/ultragenyx-receives-priority-review-rhgus-131701283.html?.tsrc=rss,"The FDA has accepted Ultragenyx Pharmaceutical Inc. (RARE)&apos;s BLA for rhGUS on a priority review basis and set a PDUFA action date of Nov 16, 2017."
RARE,RARE:UW,BBG005KLVV24,Ultragenyx Announces Recombinant Human Beta-Glucuronidase Biologics License Application and Marketing Authorization Application Filed and Accepted for Review; FDA Grants Priority Review Status,2017-05-23 12:30:00 +0000,https://finance.yahoo.com/news/ultragenyx-announces-recombinant-human-beta-123000647.html?.tsrc=rss,"NOVATO, Calif., May 23, 2017-- Ultragenyx Pharmaceutical Inc., a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced that a Biologics ..."
RARE,RARE:UW,BBG005KLVV24,Newman Ferrara LLP Announces Corporate Governance Investigation of Ultragenyx Pharmaceutical Inc.,2017-05-16 01:00:00 +0000,https://finance.yahoo.com/news/newman-ferrara-llp-announces-corporate-010000245.html?.tsrc=rss,Newman Ferrara LLP announced today that the firm is conducting an investigation on behalf of shareholders of Ultragenyx Pharmaceutical Inc. into potential breaches of fiduciary duty by the Company’s Board of Directors .
RARE,RARE:UW,BBG005KLVV24,Edited Transcript of RARE earnings conference call or presentation 4-May-17 9:00pm GMT,2017-05-10 23:40:41 +0000,http://finance.yahoo.com/news/edited-transcript-rare-earnings-conference-213133840.html?.tsrc=rss,Q1 2017 Ultragenyx Pharmaceutical Inc Earnings Call
RARE,RARE:UW,BBG005KLVV24,Ultragenyx to Present at Bank of America Merrill Lynch Healthcare Conference,2017-05-10 12:30:00 +0000,http://finance.yahoo.com/news/ultragenyx-present-bank-america-merrill-123000201.html?.tsrc=rss,"NOVATO, Calif., May 10, 2017-- Ultragenyx Pharmaceutical Inc., a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced that Emil Kakkis, ..."
RARE,RARE:UW,BBG005KLVV24,Ultragenyx reports 1Q loss,2017-05-05 09:03:53 +0000,http://finance.yahoo.com/news/ultragenyx-reports-1q-loss-090353851.html?.tsrc=rss,"On a per-share basis, the Novato, California-based company said it had a loss of $1.63. The results exceeded Wall Street expectations. The average estimate of 12 analysts surveyed by Zacks Investment Research ..."
RARE,RARE:UW,BBG005KLVV24,Ultragenyx Reports First Quarter 2017 Financial Results and Corporate Update,2017-05-04 20:05:00 +0000,http://finance.yahoo.com/news/ultragenyx-reports-first-quarter-2017-200500063.html?.tsrc=rss,"NOVATO, Calif, May 04, 2017-- Ultragenyx Pharmaceutical Inc., a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today reported its financial results ..."
RARE,RARE:UW,BBG005KLVV24,What's in Store for Catalyst (CPRX) Stock in Q1 Earnings?,2017-05-03 00:26:10 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/wsWHPXcbGxg/whats-in-store-for-catalyst-cprx-stock-in-q1-earnings-cm783131,Catalyst Pharmaceuticals Inc CPRX is expected to report first quarter 2017 results on May 11 160 Last quarter the company recorded a positive earnings surprise of 16 67 Also it topped expectations in all of the last four quarters with average positive surprise of 14 59 Catalyst
RARE,RARE:UW,BBG005KLVV24,What&apos;s in Store for Catalyst (CPRX) Stock in Q1 Earnings?,2017-05-02 22:40:10 +0000,http://finance.yahoo.com/news/apos-store-catalyst-cprx-stock-224010875.html?.tsrc=rss,"Catalyst Pharmaceuticals, Inc. (CPRX) is expected to report first-quarter 2017 results on May 11."
RARE,RARE:UW,BBG005KLVV24,Celldex Therapeutics (CLDX) Q1 Earnings: What's in Store?,2017-05-02 17:28:48 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/xxdeqjYD2BU/celldex-therapeutics-cldx-q1-earnings-whats-in-store-cm782838,Celldex Therapeutics Inc CLDX is expected to report first quarter 2017 results on May 4 Celldex s performance has been encouraging with a three quarter average positive surprise of 8 06 In the last reported quarter the company recorded a positive surprise of 11 76 Celldex
RARE,RARE:UW,BBG005KLVV24,Is ImmunoGen (IMGN) Poised for a Beat this Earnings Season?,2017-05-02 16:31:26 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/DjdjU8O3VHU/is-immunogen-imgn-poised-for-a-beat-this-earnings-season-cm782786,ImmunoGen Inc IMGN is scheduled to report first quarter 2017 results on May 5 before the opening bell ImmunoGen s track record is disappointing as the company missed expectations in all of the last four quarters Overall the company had an average negative surprise of 17
RARE,RARE:UW,BBG005KLVV24,What's in the Cards for ACADIA (ACAD) this Earnings Season?,2017-05-02 14:30:44 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/vtZDwwfOXYo/whats-in-the-cards-for-acadia-acad-this-earnings-season-cm782692,ACADIA Pharmaceuticals Inc ACAD is expected to report first quarter 2017 results on May 4 The company s track record has been dismal Evidently ACADIA missed estimates in three of the trailing four quarters bringing the average negative surprise to 13 67 In the last reported
RARE,RARE:UW,BBG005KLVV24,What to Expect from Endocyte (ECYT) Stock for Q1 Earnings?,2017-05-01 22:26:55 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/K1YtUIV0MfY/what-to-expect-from-endocyte-ecyt-stock-for-q1-earnings-cm782331,Endocyte Inc ECYT is expected to report first quarter 2017 results on May 3 In fact the company has an impressive track record having beaten estimates in three of the trailing four quarters and reporting in line results in the remaining quarter Overall the company has recorded an
RARE,RARE:UW,BBG005KLVV24,What's in Store for Zoetis (ZTS) Stock This Earnings Season?,2017-05-01 22:26:42 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/C2LMpBVjJWQ/whats-in-store-for-zoetis-zts-stock-this-earnings-season-cm782327,Zoetis Inc ZTS is scheduled to report first quarter 2017 results on May 4 before the market opens In fact the company has been seen to consistently beat earnings expectations Zoetis earnings surpassed expectations in each of the last four quarters with an average positive surprise
RARE,RARE:UW,BBG005KLVV24,What's in Store for Juno Therapeutics (JUNO) in Q1 Earnings?,2017-05-01 21:28:57 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/fBfWs8aY9o4/whats-in-store-for-juno-therapeutics-juno-in-q1-earnings-cm782309,Juno Therapeutics Inc JUNO is scheduled to report first quarter 2017 results on May 4 after the market closes Last quarter the company posted a negative earnings surprise of 4 76 Year to date Juno s shares gained 32 3 while the Zacks classified Medical Biomed Genetics
RARE,RARE:UW,BBG005KLVV24,What to Expect from Keryx (KERX) Stock This Earnings Season?,2017-04-29 00:26:11 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/btykHsiVZ9c/what-to-expect-from-keryx-kerx-stock-this-earnings-season-cm781560,Keryx Biopharmaceuticals Inc KERX is expected to report first quarter 2017 results on May 4 Last quarter the company missed expectations by 18 52 In fact Keryx s performance over the last four quarters has been disappointing The company reported a wider than expected loss in three of
RARE,RARE:UW,BBG005KLVV24,Ultragenyx to Host Conference Call for First Quarter 2017 Financial Results and Corporate Update,2017-04-28 20:05:00 +0000,http://finance.yahoo.com/news/ultragenyx-host-conference-call-first-200500551.html?.tsrc=rss,"NOVATO, Calif., April 28, 2017-- Ultragenyx Pharmaceutical Inc., a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced that it will ..."
RARE,RARE:UW,BBG005KLVV24,BioMarin (BMRN) Q1 Earnings: Will it Beat Estimates Again?,2017-04-27 17:29:32 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/PhMg_W_7qB4/biomarin-bmrn-q1-earnings-will-it-beat-estimates-again-cm780424,We expect BioMarin Pharmaceutical Inc BMRN to beat expectations when it reports first quarter 2017 results on May 4 after the market closes BioMarin had delivered a positive earnings surprise of 5 13 in the last quarter BioMarin s shares are up 16 so far this year This
RARE,RARE:UW,BBG005KLVV24,Ultragenyx Initiates Global Phase 3 Study of UX007 in Glut1 DS Patients with Disabling Movement Disorders,2017-04-27 12:30:00 +0000,http://finance.yahoo.com/news/ultragenyx-initiates-global-phase-3-123000517.html?.tsrc=rss,"NOVATO, Calif., April 27, 2017-- Ultragenyx Pharmaceutical Inc., a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced the initiation ..."
RARE,RARE:UW,BBG005KLVV24,What's in Store for Nivalis (NVLS) this Earnings Season?,2017-04-26 17:07:52 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/IqxT3MFSeBI/whats-in-store-for-nivalis-nvls-this-earnings-season-cm779678,Nivalis Therapeutics Inc NVLS is expected to report first quarter 2017 results early next month Last quarter the company had a positive surprise of 9 09 Year to date Nivalis shares lost 4 while the Zacks classified Medical Drugs industry recorded an increase of 2
RARE,RARE:UW,BBG005KLVV24,What&apos;s in Store for Nivalis (NVLS) this Earnings Season?,2017-04-26 14:30:02 +0000,http://finance.yahoo.com/news/apos-store-nivalis-nvls-earnings-143002589.html?.tsrc=rss,"Nivalis Therapeutics, Inc. (NVLS) is expected to report first-quarter 2017 results early next month. Last quarter, the company had a positive surprise of 9.09%."
RARE,RARE:UW,BBG005KLVV24,What's in Store for Vertex (VRTX) this Earnings Season?,2017-04-24 17:07:39 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/krnlnHozsVA/whats-in-store-for-vertex-vrtx-this-earnings-season-cm777990,Vertex Pharmaceuticals Inc VRTX is scheduled to report first quarter 2017 results on Apr 27 after the market closes Year to date Vertex s shares rose 58 4 while the Zacks classified Medical Biomed Genetics industry recorded an increase of 1 8 Vertex s track record
RARE,RARE:UW,BBG005KLVV24,What's in Store for AbbVie (ABBV) this Earnings Season?,2017-04-21 16:07:40 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/zxGRLX0V_zo/whats-in-store-for-abbvie-abbv-this-earnings-season-cm777086,AbbVie Inc ABBV is slated to release first quarter 2017 earnings before the opening bell on Apr 27 AbbVie s shares rose 1 8 so far this year while the Zacks classified Large Cap Pharma industry recorded an increase of 4 Last quarter the company delivered in line earnings
RARE,RARE:UW,BBG005KLVV24,Peek Under The Hood: IYH Has 11% Upside,2017-04-20 17:04:55 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/50ZyVNBpOCU/peek-under-the-hood-iyh-has-11-upside-cm776560,Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel we have compared the trading price of each holding against the average analyst 12 month forward target price and computed the weighted average implied analyst target price for the ETF itself For the
RARE,RARE:UW,BBG005KLVV24,"Company News for April 20, 2017",2017-04-20 17:03:12 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/fKl7J_I880Q/company-news-for-april-20-2017-cm776494,160 160 160 Shares of Lam Research Corporation LRCX gained 6 9 after the company reported third quarter fiscal 2017 non GAAP earnings of 2 80 per share which surpassed the Zacks Consensus Estimate of 2 54 160 160 160 Facebook s FB shares advanced 0 9 after it announced
RARE,RARE:UW,BBG005KLVV24,"Company News for April 20, 2017",2017-04-20 15:02:03 +0000,http://finance.yahoo.com/news/company-news-april-20-2017-150203596.html?.tsrc=rss,"Companies in the News are: LRCX,FB,RARE,ABT"
RARE,RARE:UW,BBG005KLVV24,"Energy, biotech, financials & more in the trader blitz",2017-04-19 20:45:00 +0000,http://finance.yahoo.com/video/energy-biotech-financials-more-trader-204500316.html?.tsrc=rss,The &quot;Halftime Report&quot; traders discuss some of the day's biggest movers.
RARE,RARE:UW,BBG005KLVV24,"Health Care Sector Update for 04/19/2017: RARE,ARGS,SSH",2017-04-19 20:22:26 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/heiJe952GWc/health-care-sector-update-for-04192017-rareargsssh-cm776088,Top Health Care StocksTop Health Care Stocks JNJ 0 39 JNJ 0 39 PFE 0 59 PFE 0 59 MRK 0 35 MRK 0 35 ABT 0 46 ABT 0 46 AMGN 0 08 AMGN 0 08 Health care stocks were helping keep the Nasdaq Composite index on positive ground late Wednesday with shares of health care companies in
RARE,RARE:UW,BBG005KLVV24,Ultragenyx's Hypophosphatemia Drug Succeeds in Phase III,2017-04-19 17:05:11 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/sim4RGA2BOU/ultragenyxs-hypophosphatemia-drug-succeeds-in-phase-iii-cm775939,Ultragenyx Pharmaceutical Inc RARE and its Japanese partner Kyowa Hakko Kirin Co Ltd announced positive data from a phase III study evaluating its pipeline candidate burosumab KRN23 in adults with X linked hypophosphatemia XLH The 24 week study met the primary endpoint as the
RARE,RARE:UW,BBG005KLVV24,Analyst Sees Ultragenyx Shares Range Bound Despite Positive Data,2017-04-19 16:14:11 +0000,http://finance.yahoo.com/news/analyst-sees-ultragenyx-shares-range-161411348.html?.tsrc=rss,"Ultragenyx Pharmaceutical Inc (NASDAQ: RARE ) announced positive data from a late-stage study of burosumab in adults with X-linked hypophosphatemia . The randomized, double-blind, placebo-controlled study ..."
RARE,RARE:UW,BBG005KLVV24,Ultragenyx&apos;s Hypophosphatemia Drug Succeeds in Phase III,2017-04-19 14:38:02 +0000,http://finance.yahoo.com/news/ultragenyx-apos-hypophosphatemia-drug-succeeds-143802444.html?.tsrc=rss,"Ultragenyx Pharmaceutical Inc. (RARE) and its Japanese partner Kyowa Hakko Kirin Co., Ltd announced positive data from a phase III study evaluating its pipeline candidate burosumab (KRN23) in adults with X-linked hypophosphatemia (XLH)."
RARE,RARE:UW,BBG005KLVV24,Why Ultragenyx Pharmaceutical Stock Is Spiking Today,2017-04-19 14:30:29 +0000,http://finance.yahoo.com/r/72ceaedd-11b8-39d4-a730-a6d680003ce8/why-ultragenyx-pharmaceutical-stock-is-spiking-tod.aspx?yptr=yahoo&.tsrc=rss,The drugmaker appears to have a potential blockbuster on its hands.
RARE,RARE:UW,BBG005KLVV24,The Next Steps For Ultragenyx' Burosumab Following Positive Phase 3 Data,2017-04-19 13:52:51 +0000,http://finance.yahoo.com/news/next-steps-ultragenyx-burosumab-following-135251801.html?.tsrc=rss,"Shares of Ultragenyx Pharmaceutical Inc (NASDAQ: RARE ), a clinical-stage bio-pharmaceutical company, were trading higher by more than 7 percent Wednesday in reaction to an encouraging update regarding ..."
RARE,RARE:UW,BBG005KLVV24,Biotech Movers: Ultragenyx Jumps on Phase Three Burosumab Data,2017-04-19 13:50:00 +0000,http://finance.yahoo.com/r/c286b1a3-8ec1-33ea-abdd-280999ef3899/biotech-movers-ultragenyx-jumps-on-phase-three-burosumab-data.html?puc=yahoo&cm_ven=YAHOO&yptr=yahoo&.tsrc=rss,"Ultragenyx, together with Kyowa Hakko Kirin and Kyowa Kirin International, on Tuesday unveiled 24-week data from a phase three study of burosumab in adults."
RARE,RARE:UW,BBG005KLVV24,Ultragenyx Pharmaceutical (RARE) Is Up On Phase 3 Study Results,2017-04-19 09:46:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/ltQaiXqD3wA/ultragenyx-pharmaceutical-rare-is-up-on-phase-3-study-results-20170419-00706,Ultragenyx Pharmaceutical (RARE) Is Up On Phase 3 Study Results
RARE,RARE:UW,BBG005KLVV24,"ARGS Gets New Lease Of Life, RARE Surges On Study Results, NVLS Abuzz",2017-04-19 03:45:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Fl_Z7IJz_04/args-gets-new-lease-of-life-rare-surges-on-study-results-nvls-abuzz-20170419-00108,"ARGS Gets New Lease Of Life, RARE Surges On Study Results, NVLS Abuzz"
RARE,RARE:UW,BBG005KLVV24,Ultragenyx surges on positive results for hypophosphatemia drug test,2017-04-18 21:37:58 +0000,http://finance.yahoo.com/r/a542f5bf-2dd0-3e17-89ad-212d33d7b8b6/Story.aspx?guid=17D74AF7-4CA7-48D0-B947-E5A8BD217083&siteid=yhoof2&yptr=yahoo&.tsrc=rss,"Shares of Ultragenyx Pharmaceutical Inc. soared in Tuesday's extended session after the company announced positive results from a phase 3 study of a drug to treat x-linked hypophosphatemia, a genetic kidney ..."
RARE,RARE:UW,BBG005KLVV24,"After-hours buzz: IBM, LRCX, RARE & more",2017-04-18 21:23:41 +0000,http://finance.yahoo.com/r/695456a4-31c6-39bb-8789-27bc4053debc/104410831?__source=yahoo%7Cfinance%7Cheadline%7Cheadline%7Cstory&par=yahoo&doc=104410831&yptr=yahoo&.tsrc=rss,These are the stocks posting the largest moves after the bell.
RARE,RARE:UW,BBG005KLVV24,"After-hours buzz: IBM, LRCX, RARE & more",2017-04-18 21:23:41 +0000,http://finance.yahoo.com/news/hours-buzz-ibm-lrcx-rare-212341608.html?.tsrc=rss,These are the stocks posting the largest moves after the bell.
RARE,RARE:UW,BBG005KLVV24,"Ultragenyx, Kyowa Hakko Kirin and Kyowa Kirin International Announce Positive 24-Week Data from Adult Phase 3 Study of Burosumab (KRN23) in X-Linked Hypophosphatemia",2017-04-18 20:01:00 +0000,http://finance.yahoo.com/news/ultragenyx-kyowa-hakko-kirin-kyowa-200100540.html?.tsrc=rss,"Study met primary endpoint of serum phosphorus response and key secondary endpoint of stiffness improvement. Ultragenyx to host conference call today at 4:30pm ET to discuss results. NOVATO, Calif., LONDON ..."
RARE,RARE:UW,BBG005KLVV24,"Ultragenyx, Kyowa Hakko Kirin and Kyowa Kirin International Announce Positive 24-week Data from Adult Phase 3 Study of Burosumab (KRN23) in X-linked Hypophosphatemia",2017-04-18 20:01:00 +0000,http://finance.yahoo.com/news/ultragenyx-kyowa-hakko-kirin-kyowa-200100599.html?.tsrc=rss,"Ultragenyx Pharmaceutical Inc. (RARE), Kyowa Hakko Kirin Co., Ltd. (Kyowa Hakko Kirin) and Kyowa Kirin International PLC, a wholly owned subsidiary of Kyowa Hakko Kirin, today announced positive 24-week data from the randomised, double-blind, placebo-controlled Phase 3 study of burosumab (KRN23) in adults with X-linked hypophosphatemia (XLH).  Patients treated with burosumab demonstrated a statistically significant improvement in serum phosphorus levels, with 94% of patients achieving normal levels compared to 8% on placebo (p<0.0001)."
RARE,RARE:UW,BBG005KLVV24,Ultragenyx's (RARE) XLH Drug Positive in Phase II Study,2017-04-10 15:58:13 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/9CzRjQ8wAg0/ultragenyxs-rare-xlh-drug-positive-in-phase-ii-study-cm772167,Ultragenyx Pharmaceutical Inc RARE and its Japanese partner Kyowa Kirin International plc recently announced positive 64 week data from a pediatric phase II study evaluating its investigational candidate burosumab KRN23 It is being developed for the treatment of X linked
RARE,RARE:UW,BBG005KLVV24,Ultragenyx&apos;s (RARE) XLH Drug Positive in Phase II Study,2017-04-10 13:34:01 +0000,http://finance.yahoo.com/news/ultragenyx-apos-rare-xlh-drug-133401921.html?.tsrc=rss,"Ultragenyx Pharmaceutical Inc. (RARE) and its Japanese partner Kyowa Kirin International plc recently announced positive 64-week data from a pediatric phase II study, evaluating its investigational candidate burosumab (KRN23)."
RARE,RARE:UW,BBG005KLVV24,"Ultragenyx Appoints Deborah Dunsire, M.D., to Board of Directors",2017-04-10 12:30:00 +0000,http://finance.yahoo.com/news/ultragenyx-appoints-deborah-dunsire-m-123000067.html?.tsrc=rss,"NOVATO, Calif., April 10, 2017-- Ultragenyx Pharmaceutical Inc., a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced the appointment ..."
RARE,RARE:UW,BBG005KLVV24,"Health Care Sector Update for 04/06/2017: RARE,AKTX,NVGN",2017-04-06 20:13:25 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/KD0bUOT4Sm0/health-care-sector-update-for-04062017-rareaktxnvgn-cm771029,Top Health Care StocksTop Health Care Stocks JNJ 0 19 JNJ 0 19 PFE 0 15 PFE 0 15 MRK 0 39 MRK 0 39 ABT 0 33 ABT 0 33 AMGN 0 14 AMGN 0 14 Health care stocks were mixed again in late trade with the NYSE Health Care Index falling less than 0 1 while shares of health care companies
RARE,RARE:UW,BBG005KLVV24,Health Care Sector Update for 04/06/2017: RARE,2017-04-06 13:53:52 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Jc5G5edBYV0/health-care-sector-update-for-04062017-rare-cm770646,Top Health care stocks Top Health care stocks JNJ flatJNJ flat PFE 0 1 PFE 0 1 ABT flatABT flat MRK 0 3 MRK 0 3 AMGN 0 1 AMGN 0 1 Health care shares were mixed in pre market trade on Thursday Health care shares were mixed in pre market trade on Thursday In health care
RARE,RARE:UW,BBG005KLVV24,Ultragenyx and Kyowa Kirin International Announce Positive Data from Paediatric Phase 2 Studies of Burosumab (KRN23) in X-Linked Hypophosphatemia,2017-04-06 12:30:00 +0000,http://finance.yahoo.com/news/ultragenyx-kyowa-kirin-international-announce-123000257.html?.tsrc=rss,"Ultragenyx Pharmaceutical Inc. (RARE) and Kyowa Kirin International PLC (KKI), a wholly owned subsidiary of Kyowa Hakko Kirin Co., Ltd. (Kyowa Hakko Kirin), today announced positive 64-week data from a paediatric Phase 2 study of burosumab (KRN23) for the treatment of X-linked hypophosphatemia (XLH) in children aged five to 12 years of age.  The data demonstrated that serum phosphorus levels, rickets, growth rates, and other functional outcomes improved with burosumab, and these treatment effects were sustained through 64 weeks of treatment."
RARE,RARE:UW,BBG005KLVV24,Ultragenyx and Kyowa Kirin International Announce Positive Data from Pediatric Phase 2 Studies of Burosumab (KRN23) in X-Linked Hypophosphatemia,2017-04-06 12:30:00 +0000,http://finance.yahoo.com/news/ultragenyx-kyowa-kirin-international-announce-123000675.html?.tsrc=rss,"NOVATO, Calif. and LONDON, April 06, 2017-- Ultragenyx Pharmaceutical Inc. and Kyowa Kirin International PLC, a wholly owned subsidiary of Kyowa Hakko Kirin Co., Ltd., today announced positive 64- week ..."
RARE,RARE:UW,BBG005KLVV24,Oversold Conditions For Ultragenyx Pharmaceutical (RARE),2017-03-29 21:58:42 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/CuLLDwT0mEI/oversold-conditions-for-ultragenyx-pharmaceutical-rare-cm767477,Legendary investor Warren Buffett advises to be fearful when others are greedy and be greedy when others are fearful One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index or RSI which measures momentum on
RARE,RARE:UW,BBG005KLVV24,RARE Makes Notable Cross Below Critical Moving Average,2017-03-24 17:00:35 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/l-GckHvASio/rare-makes-notable-cross-below-critical-moving-average-cm765311,In trading on Friday shares of Ultragenyx Pharmaceutical Inc Symbol RARE crossed below their 200 day moving average of 69 08 changing hands as low as 68 60 per share Ultragenyx Pharmaceutical Inc shares are currently trading down about 4 1 on the day The chart below shows the one
RARE,RARE:UW,BBG005KLVV24,"Ultragenyx Pharmaceutical, Inc. breached its 50 day moving average in a Bearish Manner : RARE-US : March 24, 2017",2017-03-24 12:15:15 +0000,http://finance.yahoo.com/r/ac081b2c-4b9d-3b78-ad28-73918ee433fe/ultragenyx-pharmaceutical-inc-breached-its-50-day-moving-average-in-a-bearish-manner-rare-us-march-24-2017?yptr=yahoo&.tsrc=rss,"Categories:   ETFs Yahoo Finance Click here to see latest analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Ultragenyx Pharmaceutical, Inc.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bearish Closing Price above/below 200 Day Moving ... Read more    
<b>(Read more...)</b>"
RARE,RARE:UW,BBG005KLVV24,"Ultragenyx Pharmaceutical, Inc. breached its 50 day moving average in a Bearish Manner : RARE-US : March 24, 2017",2017-03-24 12:15:15 +0000,http://www.capitalcube.com/blog/index.php/ultragenyx-pharmaceutical-inc-breached-its-50-day-moving-average-in-a-bearish-manner-rare-us-march-24-2017/,"Ultragenyx Pharmaceutical, Inc. breached its 50 day moving average in a Bearish Manner : RARE-US : March 24, 2017"
RARE,RARE:UW,BBG005KLVV24,Is It Time To Buy Ultragenxy?,2017-03-23 19:34:00 +0000,http://blogs.barrons.com/stockstowatchtoday/2017/03/23/is-it-time-to-buy-ultragenxy/?mod=yahoobarrons&ru=yahoo,Is It Time To Buy Ultragenxy?
RARE,RARE:UW,BBG005KLVV24,Is It Time To Buy Ultragenxy?,2017-03-23 19:34:00 +0000,http://finance.yahoo.com/r/77234618-f4e2-3023-840b-e08267b83d5b/is-it-time-to-buy-ultragenxy?mod=yahoobarrons&ru=yahoo&yptr=yahoo&.tsrc=rss,"Nothing guts a drug stock like bad clinical trial data. Shares of Ultragenyx Pharmaceutical (RARE) fell as much as 10% after a seizure medication failed in a phase II study. Trading at a recent $72.22, ..."
RARE,RARE:UW,BBG005KLVV24,Ultragenyx's Seizure Candidate UX007 Fails in Phase II Study,2017-03-23 16:03:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/7LIWCr-Ddh8/ultragenyxs-seizure-candidate-ux007-fails-in-phase-ii-study-cm764721,Ultragenyx Pharmaceutical Inc RARE recently announced that its pipeline candidate UX007 triheptanoin failed to meet the primary endpoint in a phase II study evaluating its safety and efficacy for the treatment of patients with glucose transporter type 1 deficiency syndrome Glut1 DS
RARE,RARE:UW,BBG005KLVV24,Ultragenyx's Seizure Candidate UX007 Fails in Phase II Study,2017-03-23 13:36:01 +0000,http://finance.yahoo.com/news/ultragenyxs-seizure-candidate-ux007-fails-133601715.html,Ultragenyx's Seizure Candidate UX007 Fails in Phase II Study
RARE,RARE:UW,BBG005KLVV24,Ultragenyx's Seizure Candidate UX007 Fails in Phase II Study,2017-03-23 13:36:01 +0000,http://finance.yahoo.com/news/ultragenyxs-seizure-candidate-ux007-fails-133601715.html?.tsrc=rss,Ultragenyx Pharmaceutical Inc. (RARE) recently announced that its pipeline candidate UX007 (triheptanoin) failed to meet the primary endpoint in a phase II study evaluating it for the treatment of patients with Glut1 DS with seizures.
RARE,RARE:UW,BBG005KLVV24,"Biotech Premarket Movers: Insys, Ultragenyx, Alexion",2017-03-23 13:36:00 +0000,http://finance.yahoo.com/r/5020fd15-0d6c-3033-aaae-558e6aedfe54/biotech-premarket-movers-insys-ultragenyx-alexion.html?puc=yahoo&cm_ven=YAHOO&yptr=yahoo&.tsrc=rss,"Insys Therapeutics, Ultragenyx Pharmaceutical and Alexion Pharmaceuticals were among the biotech stock movers in premarket trading on Thursday."
RARE,RARE:UW,BBG005KLVV24,"Biotech Premarket Movers: Insys, Ultragenyx, Alexion",2017-03-23 13:36:00 +0000,https://www.thestreet.com/story/14056918/1/biotech-premarket-movers-insys-ultragenyx-alexion.html?puc=yahoo&cm_ven=YAHOO,"Biotech Premarket Movers: Insys, Ultragenyx, Alexion"
RARE,RARE:UW,BBG005KLVV24,Ultragenyx Climbs Off Worst Levels But Continues To Post Steep Loss,2017-03-23 13:30:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/nL7gbIWyOtk/ultragenyx-climbs-off-worst-levels-but-continues-to-post-steep-loss-20170323-00909,Ultragenyx Climbs Off Worst Levels But Continues To Post Steep Loss
RARE,RARE:UW,BBG005KLVV24,Ultragenyxs’ Seizure Drug Fails Study,2017-03-23 12:43:00 +0000,http://www.investopedia.com/news/ultragenyxs-seizure-drug-fails-study-rare-mrns/?partner=YahooSA,Ultragenyxs’ Seizure Drug Fails Study
RARE,RARE:UW,BBG005KLVV24,Ultragenyxs’ Seizure Drug Fails Study,2017-03-23 12:43:00 +0000,http://finance.yahoo.com/r/4d7aeeff-a0d5-38ab-a469-f16dbc38f8cf/ultragenyxs-seizure-drug-fails-study-rare-mrns?partner=YahooSA&yptr=yahoo&.tsrc=rss,"Though the drug failed in phase 2 study, Ultragenyx has announced it plans to proceed with phase 3 studies."
RARE,RARE:UW,BBG005KLVV24,"RARE's Seizure Study Fails, HTGM Soars After-hours, NTEC Awaits Data In Q3",2017-03-23 02:34:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/gD7xSV5lZ-0/rares-seizure-study-fails-htgm-soars-afterhours-ntec-awaits-data-in-q3-20170323-00042,"RARE's Seizure Study Fails, HTGM Soars After-hours, NTEC Awaits Data In Q3"
RARE,RARE:UW,BBG005KLVV24,Ultragenyx falls on results of seizure medication study,2017-03-22 21:15:18 +0000,http://www.marketwatch.com/News/Story/Story.aspx?guid=2B0D44BC-0D4C-40E5-BB92-4EDACE106B73&siteid=yhoof2,Ultragenyx falls on results of seizure medication study
RARE,RARE:UW,BBG005KLVV24,Ultragenyx falls on results of seizure medication study,2017-03-22 21:15:18 +0000,http://finance.yahoo.com/r/efad3232-e6fd-3268-a1e0-c0090abdb98d/Story.aspx?guid=2B0D44BC-0D4C-40E5-BB92-4EDACE106B73&siteid=yhoof2&yptr=yahoo&.tsrc=rss,"Ultragenyx Pharmaceutical Inc. dropped nearly 7% in after-hours trading Wednesday after the company said a study of a potential seizure medication failed to reduce observable seizures. The study, which ..."
RARE,RARE:UW,BBG005KLVV24,Ultragenyx seizure drug fails mid-stage study,2017-03-22 21:04:11 +0000,http://finance.yahoo.com/news/ultragenyx-seizure-drug-fails-mid-210411445.html?.tsrc=rss,"Ultragenyx Pharmaceutical Inc  said its drug to treat patients with seizures did not meet the  main goal in a mid-stage study, sending its shares down 6.2  percent in after-market trading on Wednesday.  The company said the study did not show statistical  significance in reducing the frequency of seizures among  patients treated with the drug compared to a placebo, during a  eight week treatment period."
RARE,RARE:UW,BBG005KLVV24,Ultragenyx seizure drug fails mid-stage study,2017-03-22 20:24:19 +0000,http://finance.yahoo.com/news/ultragenyx-seizure-drug-fails-mid-202419848.html,Ultragenyx seizure drug fails mid-stage study
RARE,RARE:UW,BBG005KLVV24,4:05 pm Ultragenyx Pharma announces topline data from the Phase 2 study of UX007 in glucose transporter type-1 deficiency syndrome patients with seizures; study did not meet the primary endpoint,2017-03-22 20:05:00 +0000,http://finance.yahoo.com/news/inplay-briefing-com-055139997.html#rare,4:05 pm Ultragenyx Pharma announces topline data from the Phase 2 study of UX007 in glucose transporter type-1 deficiency syndrome patients with seizures; study did not meet the primary endpoint
RARE,RARE:UW,BBG005KLVV24,Ultragenyx Announces Topline Data from Phase 2 UX007 Glucose Transporter Type-1 Deficiency Syndrome Seizure Study,2017-03-22 20:05:00 +0000,http://finance.yahoo.com/news/ultragenyx-announces-topline-data-phase-200500842.html,"[GlobeNewswire] - NOVATO, Calif., March 22, 2017-- Ultragenyx Pharmaceutical Inc., a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced topline data ..."
RARE,RARE:UW,BBG005KLVV24,Ultragenyx Announces Topline Data from Phase 2 UX007 Glucose Transporter Type-1 Deficiency Syndrome Seizure Study,2017-03-22 20:05:00 +0000,http://finance.yahoo.com/news/ultragenyx-announces-topline-data-phase-200500842.html?.tsrc=rss,"NOVATO, Calif., March 22, 2017-- Ultragenyx Pharmaceutical Inc., a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced topline data ..."
RARE,RARE:UW,BBG005KLVV24,Ultragenyx to Present at Upcoming Investor Conferences,2017-03-02 13:30:00 +0000,http://finance.yahoo.com/news/ultragenyx-present-upcoming-investor-conferences-133000415.html?.tsrc=rss,"NOVATO, Calif., March 02, 2017-- Ultragenyx Pharmaceutical Inc., a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, will present at the following ..."
RARE,RARE:UW,BBG005KLVV24,Ultragenyx to Present at Upcoming Investor Conferences,2017-03-02 13:30:00 +0000,http://finance.yahoo.com/news/ultragenyx-present-upcoming-investor-conferences-133000415.html,"[GlobeNewswire] - NOVATO, Calif., March 02, 2017-- Ultragenyx Pharmaceutical Inc., a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, will present at the following ..."
RARE,RARE:UW,BBG005KLVV24,ULTRAGENYX PHARMACEUTICAL INC. Financials,2017-02-22 18:04:24 +0000,http://finance.yahoo.com/q/is?s=rare,ULTRAGENYX PHARMACEUTICAL INC. Financials
RARE,RARE:UW,BBG005KLVV24,"Notable Tuesday Option Activity: NCLH, RARE, WYNN",2017-02-21 22:07:02 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/X10QfcZpxYo/notable-tuesday-option-activity-nclh-rare-wynn-cm750904,Looking at options trading activity among components of the Russell 3000 index there is noteworthy activity today in Norwegian Cruise Line Holdings Ltd Symbol NCLH where a total volume of 5 973 contracts has been traded thus far today a contract volume which is representative
RARE,RARE:UW,BBG005KLVV24,Baron Opportunity Fund Comments on Ultragenyx Pharmaceutical,2017-02-21 16:56:34 +0000,http://finance.yahoo.com/news/baron-opportunity-fund-comments-ultragenyx-165634503.html?.tsrc=rss,Guru stock highlight
RARE,RARE:UW,BBG005KLVV24,Baron Opportunity Fund Comments on Ultragenyx Pharmaceutical,2017-02-21 16:56:34 +0000,http://finance.yahoo.com/news/baron-opportunity-fund-comments-ultragenyx-165634503.html,Baron Opportunity Fund Comments on Ultragenyx Pharmaceutical
RARE,RARE:UW,BBG005KLVV24,"ULTRAGENYX PHARMACEUTICAL INC. Files SEC form 10-K, Annual Report",2017-02-17 11:06:09 +0000,http://biz.yahoo.com/e/170217/rare10-k.html,"ULTRAGENYX PHARMACEUTICAL INC. Files SEC form 10-K, Annual Report"
RARE,RARE:UW,BBG005KLVV24,Edited Transcript of RARE earnings conference call or presentation 16-Feb-17 10:00pm GMT,2017-02-17 05:01:40 +0000,http://finance.yahoo.com/news/edited-transcript-rare-earnings-conference-050140667.html,Edited Transcript of RARE earnings conference call or presentation 16-Feb-17 10:00pm GMT
RARE,RARE:UW,BBG005KLVV24,Edited Transcript of RARE earnings conference call or presentation 16-Feb-17 10:00pm GMT,2017-02-17 05:01:40 +0000,http://finance.yahoo.com/news/edited-transcript-rare-earnings-conference-050140667.html?.tsrc=rss,Q4 2016 Ultragenyx Pharmaceutical Inc Earnings Call
RARE,RARE:UW,BBG005KLVV24,Ultragenyx reports 4Q loss,2017-02-16 21:42:50 +0000,http://finance.yahoo.com/news/ultragenyx-reports-4q-loss-214250232.html?.tsrc=rss,"On a per-share basis, the Novato, California-based company said it had a loss of $1.75. The results did not meet Wall Street expectations. The average estimate of 12 analysts surveyed by Zacks Investment ..."
RARE,RARE:UW,BBG005KLVV24,Ultragenyx reports 4Q loss,2017-02-16 21:42:50 +0000,http://sg.finance.yahoo.com/news/ultragenyx-reports-4q-loss-214250285.html,Ultragenyx reports 4Q loss
RARE,RARE:UW,BBG005KLVV24,"ULTRAGENYX PHARMACEUTICAL INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statement",2017-02-16 21:10:53 +0000,http://biz.yahoo.com/e/170216/rare8-k.html,"ULTRAGENYX PHARMACEUTICAL INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statement"
RARE,RARE:UW,BBG005KLVV24,Ultragenyx Reports Fourth Quarter and Full Year 2016 Financial Results and Corporate Update,2017-02-16 21:05:00 +0000,http://finance.yahoo.com/news/ultragenyx-reports-fourth-quarter-full-210500904.html,"[GlobeNewswire] - NOVATO, Calif., Feb. 16, 2017-- Ultragenyx Pharmaceutical Inc., a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today reported its financial results ..."
RARE,RARE:UW,BBG005KLVV24,Ultragenyx Reports Fourth Quarter and Full Year 2016 Financial Results and Corporate Update,2017-02-16 21:05:00 +0000,http://finance.yahoo.com/news/ultragenyx-reports-fourth-quarter-full-210500904.html?.tsrc=rss,"NOVATO, Calif., Feb. 16, 2017-- Ultragenyx Pharmaceutical Inc., a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today reported its financial results ..."
RARE,RARE:UW,BBG005KLVV24,Q4 2016 Ultragenyx Pharmaceutical Inc Earnings Release - After Market Close,2017-02-16 12:07:04 +0000,http://biz.yahoo.com/research/earncal/20170216.html?t=rare,Q4 2016 Ultragenyx Pharmaceutical Inc Earnings Release - After Market Close
RARE,RARE:UW,BBG005KLVV24,"Drug Stocks Q4 Earnings Slated for Feb 16: ALXN, ZTS & More",2017-02-15 13:47:01 +0000,http://finance.yahoo.com/news/drug-stocks-q4-earnings-slated-134701280.html?.tsrc=rss,The Q4 earnings season is on its last legs as results from 358 S&P 500 members or 71.6% of the index's total membership is already out.
RARE,RARE:UW,BBG005KLVV24,"Drug Stocks Q4 Earnings Slated for Feb 16: ALXN, ZTS & More",2017-02-15 13:47:01 +0000,http://finance.yahoo.com/news/drug-stocks-q4-earnings-slated-134701280.html,"Drug Stocks Q4 Earnings Slated for Feb 16: ALXN, ZTS & More"
RARE,RARE:UW,BBG005KLVV24,Abeona: Preparing For Liftoff - The Next Avexis?,2017-02-14 15:18:20 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/-b2MqGaF2SE/abeona-preparing-for-liftoff-the-next-avexis-cm747604,By World s Greatest ByWorld s Greatest Executive Summary and Investment Thesis Executive Summary and Investment ThesisExecutive Summary and Investment Thesis Abeona Therapeutics ABEO is a biotechnology company with a number of early and late stage assets This week the company
RARE,RARE:UW,BBG005KLVV24,Ultragenyx to Present at Leerink Partners Global Healthcare Conference,2017-02-10 13:30:00 +0000,http://finance.yahoo.com/news/ultragenyx-present-leerink-partners-global-133000079.html?.tsrc=rss,"NOVATO, Calif., Feb. 10, 2017-- Ultragenyx Pharmaceutical Inc., a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced that Shalini Sharp, ..."
RARE,RARE:UW,BBG005KLVV24,Ultragenyx to Present at Leerink Partners Global Healthcare Conference,2017-02-10 13:30:00 +0000,http://finance.yahoo.com/news/ultragenyx-present-leerink-partners-global-133000079.html,"[GlobeNewswire] - NOVATO, Calif., Feb. 10, 2017-- Ultragenyx Pharmaceutical Inc., a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced that Shalini Sharp, ..."
RARE,RARE:UW,BBG005KLVV24,Ultragenyx to Host Conference Call for Fourth Quarter and Full Year 2016 Financial Results and Corporate Update,2017-02-09 21:07:03 +0000,http://finance.yahoo.com/news/ultragenyx-host-conference-call-fourth-210703684.html,"[GlobeNewswire] - NOVATO, Calif., Feb. 09, 2017-- Ultragenyx Pharmaceutical Inc., a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced that it will host ..."
RARE,RARE:UW,BBG005KLVV24,Ultragenyx to Host Conference Call for Fourth Quarter and Full Year 2016 Financial Results and Corporate Update,2017-02-09 21:07:03 +0000,http://finance.yahoo.com/news/ultragenyx-host-conference-call-fourth-210703684.html?.tsrc=rss,"NOVATO, Calif., Feb. 09, 2017-- Ultragenyx Pharmaceutical Inc., a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced that it will host ..."
RARE,RARE:UW,BBG005KLVV24,"Ultragenyx Pharmaceutical, Inc. breached its 50 day moving average in a Bullish Manner : RARE-US : February 1, 2017",2017-02-01 12:33:21 +0000,http://www.capitalcube.com/blog/index.php/ultragenyx-pharmaceutical-inc-breached-its-50-day-moving-average-in-a-bullish-manner-rare-us-february-1-2017/,"Ultragenyx Pharmaceutical, Inc. breached its 50 day moving average in a Bullish Manner : RARE-US : February 1, 2017"
RARE,RARE:UW,BBG005KLVV24,"Gainers & Losers Of The Day: MNTA, BLCM, VSAR, TENX, DMTX...",2017-01-31 23:33:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/VCATEAIBluI/gainers--losers-of-the-day-mnta-blcm-vsar-tenx-dmtx-20170131-01699,"Gainers & Losers Of The Day: MNTA, BLCM, VSAR, TENX, DMTX..."
RARE,RARE:UW,BBG005KLVV24,Sum Up The Parts: IYH Could Be Worth $169,2017-01-18 15:38:18 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Zp-fQzju0ic/sum-up-the-parts-iyh-could-be-worth-169-cm734707,Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel we have compared the trading price of each holding against the average analyst 12 month forward target price and computed the weighted average implied analyst target price for the ETF itself For the
RARE,RARE:UW,BBG005KLVV24,Ultragenyx's (RARE) KRN23 Accepted for Review in the EU,2017-01-06 14:40:28 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/VYMHsePO6D0/ultragenyxs-rare-krn23-accepted-for-review-in-the-eu-cm730343,Ultragenyx Pharmaceutical Inc RARE announced that the European Medicines Agency EMA has accepted to review the company s Marketing Authorization Application MAA for KRN23 for the treatment of X linked hypophosphatemia XLH KRN23 an antibody targeting fibroblast growth factor
RARE,RARE:UW,BBG005KLVV24,Ultragenyx's (RARE) KRN23 Accepted for Review in the EU,2017-01-06 13:18:01 +0000,http://finance.yahoo.com/news/ultragenyxs-rare-krn23-accepted-review-131801746.html,Ultragenyx's (RARE) KRN23 Accepted for Review in the EU
RARE,RARE:UW,BBG005KLVV24,"Ultragenyx Pharmaceutical, Inc. breached its 50 day moving average in a Bullish Manner : RARE-US : January 5, 2017",2017-01-05 13:18:50 +0000,http://www.capitalcube.com/blog/index.php/ultragenyx-pharmaceutical-inc-breached-its-50-day-moving-average-in-a-bullish-manner-rare-us-january-5-2017/,"Ultragenyx Pharmaceutical, Inc. breached its 50 day moving average in a Bullish Manner : RARE-US : January 5, 2017"
RARE,RARE:UW,BBG005KLVV24,Ultragenyx and Kyowa Kirin International Announce Marketing Authorization Application for KRN23 Filed and Accepted for Review by European Medicines Agency,2017-01-05 07:14:07 +0000,http://www.publicnow.com/view/7603E5F273CE31BC0EA8D6E9E68B15532B935822,"[at noodls] - NOVATO, Calif. and LONDON, Jan. 05, 2017 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) and Kyowa Kirin International PLC (KKI), a wholly owned subsidiary of Kyowa Hakko Kirin Co., Ltd. ..."
RARE,RARE:UW,BBG005KLVV24,Ultragenyx and Kyowa Kirin International Announce Marketing Authorisation Application for KRN23 Filed and Accepted for Review by European Medicines Agency(106KB),2017-01-05 07:04:05 +0000,http://www.publicnow.com/view/1C39529CF4A3B278AB8CFAAAA7026B098A8A489E,"[at noodls] - Ultragenyx and Kyowa Kirin International Announce Marketing Authorisation Application for KRN23 Filed and Accepted for Review by European Medicines Agency Novato, CA and London, UK - January 5, 2017 - ..."
RARE,RARE:UW,BBG005KLVV24,Ultragenyx and Kyowa Kirin International Announce Marketing Authorisation Application for KRN23 Filed and Accepted for Review by European Medicines Agency,2017-01-05 07:00:00 +0000,http://finance.yahoo.com/news/ultragenyx-kyowa-kirin-international-announce-070000284.html,"[PR Newswire] - Ultragenyx Pharmaceutical Inc. (RARE) and Kyowa Kirin International PLC (KKI), a wholly owned subsidiary of Kyowa Hakko Kirin Co., Ltd. (Kyowa Hakko Kirin), today announced that the European Medicines Agency (EMA) has accepted for review the Marketing Authorisation Application (MAA) for KRN23 for the treatment of X-linked hypophosphatemia (XLH). Ultragenyx and Kyowa Hakko Kirin entered into a collaboration and licence agreement in August 2013 to develop and commercialise KRN23. ""Based on the positive results from multiple studies in paediatric and adult patients with XLH, we are pursuing conditional marketing authorisation in order to accelerate access to this therapy for patients,"" said Emil D. Kakkis, M.D., Ph.D., Chief Executive Officer and President of Ultragenyx."
RARE,RARE:UW,BBG005KLVV24,Ultragenyx and Kyowa Kirin International Announce Marketing Authorization Application for KRN23 Filed and Accepted for Review by European Medicines Agency,2017-01-05 07:00:00 +0000,http://finance.yahoo.com/news/ultragenyx-kyowa-kirin-international-announce-070000549.html,"[GlobeNewswire] - NOVATO, Calif. and LONDON, Jan. 05, 2017-- Ultragenyx Pharmaceutical Inc. and Kyowa Kirin International PLC, a wholly owned subsidiary of Kyowa Hakko Kirin Co., Ltd., today announced that the European ..."
RARE,RARE:UW,BBG005KLVV24,Ultragenyx And KKI Say MAA For KRN23 Filed And Accepted For Review By EMA,2017-01-05 02:14:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/rHLAeVEzeHs/ultragenyx-and-kki-say-maa-for-krn23-filed-and-accepted-for-review-by-ema-20170105-00045,Ultragenyx And KKI Say MAA For KRN23 Filed And Accepted For Review By EMA
RARE,RARE:UW,BBG005KLVV24,Ultragenyx to Present at J.P. Morgan Healthcare Conference,2017-01-04 13:30:00 +0000,http://finance.yahoo.com/news/ultragenyx-present-j-p-morgan-133000137.html,"[GlobeNewswire] - NOVATO, Calif., Jan. 04, 2017-- Ultragenyx Pharmaceutical Inc., a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced that Emil D. Kakkis, ..."
RARE,RARE:UW,BBG005KLVV24,"Ultragenyx Pharmaceutical, Inc. breached its 50 day moving average in a Bearish Manner : RARE-US : December 23, 2016",2016-12-23 12:41:30 +0000,http://www.capitalcube.com/blog/index.php/ultragenyx-pharmaceutical-inc-breached-its-50-day-moving-average-in-a-bearish-manner-rare-us-december-23-2016/,"Ultragenyx Pharmaceutical, Inc. breached its 50 day moving average in a Bearish Manner : RARE-US : December 23, 2016"
RARE,RARE:UW,BBG005KLVV24,"ETFs with exposure to Ultragenyx Pharmaceutical, Inc. : December 14, 2016",2016-12-14 16:58:25 +0000,http://www.capitalcube.com/blog/index.php/etfs-with-exposure-to-ultragenyx-pharmaceutical-inc-december-14-2016/,"ETFs with exposure to Ultragenyx Pharmaceutical, Inc. : December 14, 2016"
RARE,RARE:UW,BBG005KLVV24,"Ultragenyx Pharmaceutical, Inc. – Value Analysis (NASDAQ:RARE) : December 13, 2016",2016-12-13 15:50:32 +0000,http://www.capitalcube.com/blog/index.php/ultragenyx-pharmaceutical-inc-value-analysis-nasdaqrare-december-13-2016/,"Ultragenyx Pharmaceutical, Inc. – Value Analysis (NASDAQ:RARE) : December 13, 2016"
RARE,RARE:UW,BBG005KLVV24,"Should You Buy MB Financial, Inc. (MBFI)?",2016-12-12 18:08:51 +0000,http://www.insidermonkey.com/blog/should-you-buy-mb-financial-inc-mbfi-505508/,"Should You Buy MB Financial, Inc. (MBFI)?"
RARE,RARE:UW,BBG005KLVV24,"Ultragenyx Pharmaceutical, Inc. breached its 50 day moving average in a Bearish Manner : RARE-US : December 12, 2016",2016-12-12 12:45:16 +0000,http://www.capitalcube.com/blog/index.php/ultragenyx-pharmaceutical-inc-breached-its-50-day-moving-average-in-a-bearish-manner-rare-us-december-12-2016/,"Ultragenyx Pharmaceutical, Inc. breached its 50 day moving average in a Bearish Manner : RARE-US : December 12, 2016"
RARE,RARE:UW,BBG005KLVV24,Hedge Funds Are Dumping Ultragenyx Pharmaceutical Inc (RARE),2016-12-09 13:51:03 +0000,http://www.insidermonkey.com/blog/hedge-funds-are-dumping-ultragenyx-pharmaceutical-inc-rare-501600/,Hedge Funds Are Dumping Ultragenyx Pharmaceutical Inc (RARE)
RARE,RARE:UW,BBG005KLVV24,Peek Under The Hood: IYH Has 19% Upside,2016-12-08 15:58:19 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/KzPaaTKtnog/peek-under-the-hood-iyh-has-19-upside-cm718531,Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel we have compared the trading price of each holding against the average analyst 12 month forward target price and computed the weighted average implied analyst target price for the ETF itself For the
RARE,RARE:UW,BBG005KLVV24,"ULTRAGENYX PHARMACEUTICAL INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits",2016-12-02 21:18:26 +0000,http://biz.yahoo.com/e/161202/rare8-k.html,"ULTRAGENYX PHARMACEUTICAL INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits"
RARE,RARE:UW,BBG005KLVV24,Ultragenyx (RARE) Reports Positive Phase II Study on UX007,2016-12-01 17:21:33 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/IKq4uj6boWg/ultragenyx-rare-reports-positive-phase-ii-study-on-ux007-cm716395,Ultragenyx Pharmaceutical Inc RARE announced positive data from a phase II study on UX007 triheptanoin for the treatment of patients with long chain fatty acid oxidation disorder LC FAOD The data was collected at the end of the 78 week treatment period The single arm open label
RARE,RARE:UW,BBG005KLVV24,Ultragenyx Announces Positive Data from Phase 2 Study of UX007 in Long-Chain Fatty Acid Oxidation Disorder Patients,2016-12-01 15:22:48 +0000,http://www.publicnow.com/view/45A6F071DE378B6B35DEF7066CFAC48F80BF2E87,"[at noodls] - Reductions observed in frequency and total duration of major medical events NOVATO, Calif., Nov. 30, 2016 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused ..."
RARE,RARE:UW,BBG005KLVV24,Ultragenyx (RARE) Reports Positive Phase II Study on UX007,2016-12-01 15:17:03 +0000,http://finance.yahoo.com/news/ultragenyx-rare-reports-positive-phase-151703368.html,Ultragenyx (RARE) Reports Positive Phase II Study on UX007
RARE,RARE:UW,BBG005KLVV24,"It's All Green For BLUE, HTBX Plunges On Failed Study, Watch Out For BPMC",2016-12-01 00:33:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/tDge2q3p8Iw/its-all-green-for-blue-htbx-plunges-on-failed-study-watch-out-for-bpmc-20161201-00015,"It's All Green For BLUE, HTBX Plunges On Failed Study, Watch Out For BPMC"
RARE,RARE:UW,BBG005KLVV24,Ultragenyx Announces Positive Data from Phase 2 Study of UX007 in Long-Chain Fatty Acid Oxidation Disorder Patients,2016-11-30 13:30:00 +0000,http://finance.yahoo.com/news/ultragenyx-announces-positive-data-phase-133000499.html,"[GlobeNewswire] - Reductions observed in frequency and total duration of major medical events. NOVATO, Calif., Nov. 30, 2016-- Ultragenyx Pharmaceutical Inc., a biopharmaceutical company focused on the development of novel ..."
RARE,RARE:UW,BBG005KLVV24,Blog Coverage Lion Biotechnologies Signs a New Manufacturing Services Agreement with WuXi AppTec for its Cell Therapy Products,2016-11-29 13:15:00 +0000,http://finance.yahoo.com/news/blog-coverage-lion-biotechnologies-signs-131500658.html,"[Accesswire] - Upcoming AWS Coverage on Ultragenyx Pharmaceutical Post-Earnings Results LONDON, UK / ACCESSWIRE / November 29, 2016 / Active Wall St. blog coverage looks at the headline from Lion Biotechnologies, Inc. ..."
RARE,RARE:UW,BBG005KLVV24,Ultragenyx To Present At Stifel Healthcare Conference; Webcast At 1:30 PM ET,2016-11-15 12:30:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/hGS49qaTurI/ultragenyx-to-present-at-stifel-healthcare-conference-webcast-at-130-pm-et-20161115-01025,Ultragenyx To Present At Stifel Healthcare Conference; Webcast At 1:30 PM ET
RARE,RARE:UW,BBG005KLVV24,"ULTRAGENYX PHARMACEUTICAL INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits",2016-11-14 22:08:50 +0000,http://biz.yahoo.com/e/161114/rare8-k.html,"ULTRAGENYX PHARMACEUTICAL INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits"
RARE,RARE:UW,BBG005KLVV24,Ultragenyx Pharma downgraded by Citigroup,2016-11-14 13:15:36 +0000,http://finance.yahoo.com/q/ud?s=RARE,Ultragenyx Pharma downgraded by Citigroup
RARE,RARE:UW,BBG005KLVV24,Stocks Remain Mixed In Mid-Day Trading - U.S. Commentary,2016-11-14 12:07:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/ZC-qIGsUS6w/stocks-remain-mixed-in-midday-trading--us-commentary-20161114-00934,Stocks Remain Mixed In Mid-Day Trading - U.S. Commentary
RARE,RARE:UW,BBG005KLVV24,Stocks May Show A Lack Of Direction In Early Trading - U.S. Commentary,2016-11-14 08:50:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/K2PVDHIrLXA/stocks-may-show-a-lack-of-direction-in-early-trading--us-commentary-20161114-00579,Stocks May Show A Lack Of Direction In Early Trading - U.S. Commentary
RARE,RARE:UW,BBG005KLVV24,"AMGN Crosses BRIDGE, Anxiety Over PTCT''s Translarna Eases, EGRX Opens Wallet",2016-11-13 00:06:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/WUmrN9QYVXY/amgn-crosses-bridge-anxiety-over-ptcts-translarna-eases-egrx-opens-wallet-20161113-00001,"AMGN Crosses BRIDGE, Anxiety Over PTCT''s Translarna Eases, EGRX Opens Wallet"
RARE,RARE:UW,BBG005KLVV24,Ultragenyx Announces Withdrawal of Marketing Authorization Application for Aceneuramic Acid Prolonged Release (Ace-ER) in the European Union,2016-11-11 13:37:05 +0000,http://www.publicnow.com/view/9C754DB7DDBB2750049CD433C0AE1CED1A00BBAC,"[at noodls] - NOVATO, Calif., Nov. 11, 2016 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, ..."
RARE,RARE:UW,BBG005KLVV24,"Ultragenyx Pharmaceutical, Inc. breached its 50 day moving average in a Bullish Manner : RARE-US : November 11, 2016",2016-11-11 12:12:19 +0000,http://www.capitalcube.com/blog/index.php/ultragenyx-pharmaceutical-inc-breached-its-50-day-moving-average-in-a-bullish-manner-rare-us-november-11-2016/,"Ultragenyx Pharmaceutical, Inc. breached its 50 day moving average in a Bullish Manner : RARE-US : November 11, 2016"
RARE,RARE:UW,BBG005KLVV24,Ultragenyx Pharmaceutical Breaks Above 200-Day Moving Average - Bullish for RARE,2016-11-09 19:52:41 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/C-mPfl3qLvo/ultragenyx-pharmaceutical-breaks-above-200-day-moving-average-bullish-for-rare-cm706654,In trading on Wednesday shares of Ultragenyx Pharmaceutical Inc Symbol RARE crossed above their 200 day moving average of 63 24 changing hands as high as 76 31 per share Ultragenyx Pharmaceutical Inc shares are currently trading up about 10 8 on the day The chart below shows the one
RARE,RARE:UW,BBG005KLVV24,Ultragenyx to Present at Upcoming Investor Conferences,2016-11-08 13:37:08 +0000,http://www.publicnow.com/view/D77B8A0A154FFDAE14610837B893F6C505911A7D,"[at noodls] - NOVATO, Calif., Nov. 08, 2016 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, ..."
RARE,RARE:UW,BBG005KLVV24,"ULTRAGENYX PHARMACEUTICAL INC. Files SEC form 10-Q, Quarterly Report",2016-11-08 11:10:10 +0000,http://biz.yahoo.com/e/161108/rare10-q.html,"ULTRAGENYX PHARMACEUTICAL INC. Files SEC form 10-Q, Quarterly Report"
RARE,RARE:UW,BBG005KLVV24,Edited Transcript of RARE earnings conference call or presentation 7-Nov-16 10:00pm GMT,2016-11-08 07:36:08 +0000,http://finance.yahoo.com/news/edited-transcript-rare-earnings-conference-073608100.html,Edited Transcript of RARE earnings conference call or presentation 7-Nov-16 10:00pm GMT
RARE,RARE:UW,BBG005KLVV24,Ultragenyx reports 3Q loss,2016-11-07 21:52:50 +0000,http://sg.finance.yahoo.com/news/ultragenyx-reports-3q-loss-215250283.html,Ultragenyx reports 3Q loss
RARE,RARE:UW,BBG005KLVV24,"ULTRAGENYX PHARMACEUTICAL INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statement",2016-11-07 21:21:43 +0000,http://biz.yahoo.com/e/161107/rare8-k.html,"ULTRAGENYX PHARMACEUTICAL INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statement"
RARE,RARE:UW,BBG005KLVV24,Ultragenyx Reports Third Quarter 2016 Financial Results and Corporate Update,2016-11-07 21:20:10 +0000,http://www.publicnow.com/view/6E8FDDD2951C85E377BCC618DA13CA4836C2F265,"[at noodls] - NOVATO, Calif., Nov. 07, 2016 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, ..."
RARE,RARE:UW,BBG005KLVV24,Ultragenyx Pharmaceutical Q3 16 Earnings Conference Call At 5:00 PM ET,2016-11-07 15:00:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/vbJpUgsWA-s/ultragenyx-pharmaceutical-q3-16-earnings-conference-call-at-500-pm-et-20161107-01080,Ultragenyx Pharmaceutical Q3 16 Earnings Conference Call At 5:00 PM ET
RARE,RARE:UW,BBG005KLVV24,Q3 2016 Ultragenyx Pharmaceutical Inc Earnings Release - After Market Close,2016-11-07 12:07:06 +0000,http://biz.yahoo.com/research/earncal/20161107.html?t=rare,Q3 2016 Ultragenyx Pharmaceutical Inc Earnings Release - After Market Close
RARE,RARE:UW,BBG005KLVV24,"Drug Stocks Earnings Roster for Nov 7: HZNP, ACAD & More",2016-11-04 12:54:12 +0000,http://finance.yahoo.com/news/drug-stocks-earnings-roster-nov-125412689.html,"Drug Stocks Earnings Roster for Nov 7: HZNP, ACAD & More"
RARE,RARE:UW,BBG005KLVV24,Ultragenyx Pharmaceutical Enters Oversold Territory (RARE),2016-11-03 18:08:07 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/RdjXEsxloC8/ultragenyx-pharmaceutical-enters-oversold-territory-rare-cm703444,Legendary investor Warren Buffett advises to be fearful when others are greedy and be greedy when others are fearful One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index or RSI which measures momentum on
RARE,RARE:UW,BBG005KLVV24,Ultragenyx to Host Conference Call for Third Quarter 2016 Financial Results and Corporate Update,2016-10-31 12:33:06 +0000,http://www.publicnow.com/view/001E8945AD9B603499424B7182FF6B0E0C3F552D,"[at noodls] - NOVATO, Calif., Oct. 31, 2016 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, ..."
RARE,RARE:UW,BBG005KLVV24,Interesting RARE Put And Call Options For December 16th,2016-10-27 15:42:37 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/idSinIVoBX4/interesting-rare-put-and-call-options-for-december-16th-cm699464,Investors in Ultragenyx Pharmaceutical Inc Symbol RARE saw new options become available this week for the December 16th expiration At Stock Options Channel our YieldBoost formula has looked up and down the RARE options chain for the new December 16th contracts and identified one put and
RARE,RARE:UW,BBG005KLVV24,Ultragenyx Announces First Patient Enrolled in Global Phase 3 Study of KRN23 in Pediatric Patients with X-Linked Hypophosphatemia (XLH),2016-10-26 12:45:03 +0000,http://www.publicnow.com/view/84A2D71139E04599CBAB7DD7FD24183C67B7552D,"[at noodls] - NOVATO, Calif, Oct. 26, 2016 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, ..."
RARE,RARE:UW,BBG005KLVV24,"Commit To Buy Ultragenyx Pharmaceutical At $50, Earn 13.8% Annualized Using Options",2016-10-25 17:24:53 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/TU0PseImB6M/commit-to-buy-ultragenyx-pharmaceutical-at-50-earn-138-annualized-using-options-cm698000,Investors eyeing a purchase of Ultragenyx Pharmaceutical Inc Symbol RARE stock but cautious about paying the going market price of 64 38 share might benefit from considering selling puts among the alternative strategies at their disposal One interesting put contract in particular is the
RARE,RARE:UW,BBG005KLVV24,"Thursday's ETF Movers: XBI, XME",2016-10-20 15:27:23 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/2FQJ5l5sylo/thursdays-etf-movers-xbi-xme-cm695930,In trading on Thursday the SPDR S amp P Biotech ETF XBI is outperforming other ETFs up about 1 2 on the day Components of that ETF showing particular strength include shares of Ultragenyx Pharmaceutical RARE up about 5 5 and shares of Alder Biopharmaceuticals ALDR up
RARE,RARE:UW,BBG005KLVV24,"ETF’s with exposure to Ultragenyx Pharmaceutical, Inc. : October 18, 2016",2016-10-18 15:00:23 +0000,http://www.capitalcube.com/blog/index.php/etfs-with-exposure-to-ultragenyx-pharmaceutical-inc-october-18-2016/,"ETF’s with exposure to Ultragenyx Pharmaceutical, Inc. : October 18, 2016"
RARE,RARE:UW,BBG005KLVV24,"Ultragenyx Pharmaceutical, Inc. breached its 50 day moving average in a Bearish Manner : RARE-US : October 13, 2016",2016-10-13 12:28:26 +0000,http://www.capitalcube.com/blog/index.php/ultragenyx-pharmaceutical-inc-breached-its-50-day-moving-average-in-a-bearish-manner-rare-us-october-13-2016/,"Ultragenyx Pharmaceutical, Inc. breached its 50 day moving average in a Bearish Manner : RARE-US : October 13, 2016"
RARE,RARE:UW,BBG005KLVV24,"Biotechs Worst-Performing Stocks Wednesday; Prothena, Supernus Fall",2016-10-12 20:22:01 +0000,http://www.investors.com/news/technology/biotechs-worst-performing-stocks-wednesday-prothena-supernus-fall/,"Biotechs Worst-Performing Stocks Wednesday; Prothena, Supernus Fall"
RARE,RARE:UW,BBG005KLVV24,Alexion Presents New Long-Term Phase III Data on Kanuma,2016-10-11 15:21:38 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/RBoWQ9DXcKI/alexion-presents-new-long-term-phase-iii-data-on-kanuma-cm691774,Alexion Pharmaceuticals Inc ALXN announced that new long term data from an ongoing open label extension of the pivotal phase III ARISE study on Kanuma in children and adults suffering from lysosomal acid lipase deficiency LAL D were presented at the World Congress of
RARE,RARE:UW,BBG005KLVV24,Fidelity Denies Report It Favored Its Venture Group Over Mutual Funds,2016-10-05 21:42:43 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/GEAboEfyqNo/fidelity-denies-report-it-favored-its-venture-group-over-mutual-funds-cm689436,Fidelity Investments on Wednesday refuted a Reuters news service article that contends the Johnson family which runs the mutual fund giant creates a conflict of interest by also having a 160 private venture capital business that competes for access to stocks The VC group F
RARE,RARE:UW,BBG005KLVV24,Fidelity Denies Report It Favored Its Venture Group Over Mutual Funds,2016-10-05 19:35:20 +0000,http://www.investors.com/etfs-and-funds/mutual-funds/fidelity-owners-can-make-lucrative-investments-before-their-funds-reuters-says/,Fidelity Denies Report It Favored Its Venture Group Over Mutual Funds
RARE,RARE:UW,BBG005KLVV24,Stock Exchange: The Risk/On Risk/Off Debate Rages,2016-10-02 09:44:14 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/tDhzFmQlPS8/stock-exchange-the-riskon-riskoff-debate-rages-cm683624,By Jeff Miller ByJeff Miller Technical experts are a rich source of new stock ideas Our trading models each specialize in a different time frame and level of risk Before their weekly poker game they spend a few minutes trading ideas They like to call this their Stock Exchange I am
RARE,RARE:UW,BBG005KLVV24,Ultragenyx to Present at Leerink Partners Roundtable Series,2016-09-27 12:39:09 +0000,http://www.publicnow.com/view/BDB821FA0A23A5437353E3BFF9C6003D0C4A15DA,"[at noodls] - NOVATO, Calif., Sept. 27, 2016 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, ..."
RARE,RARE:UW,BBG005KLVV24,Jefferies Highlights Clinically Meaningful Data From Ultragenyx On KRN23,2016-09-20 17:46:15 +0000,http://finance.yahoo.com/news/jefferies-highlights-clinically-meaningful-data-174615666.html,Jefferies Highlights Clinically Meaningful Data From Ultragenyx On KRN23
RARE,RARE:UW,BBG005KLVV24,"Why Sarepta Approval is Good News for BioMarin, Alexion",2016-09-20 15:32:00 +0000,http://blogs.barrons.com/stockstowatchtoday/2016/09/20/why-sarepta-approval-is-good-news-for-biomarin-alexion/?mod=yahoobarrons&ru=yahoo,"Why Sarepta Approval is Good News for BioMarin, Alexion"
RARE,RARE:UW,BBG005KLVV24,Ultragenyx Reports Positive Interim Data from Pediatric and Adult Phase 2 Studies of KRN23 in X-Linked Hypophosphatemia,2016-09-19 14:45:00 +0000,http://finance.yahoo.com/news/ultragenyx-reports-positive-interim-data-144500708.html,[GlobeNewswire] - Pediatric study demonstrates substantial reduction in bone disease and improvement in growth. Adult study demonstrates increase in serum phosphorus and provides evidence of clinical improvement. Company ...
RARE,RARE:UW,BBG005KLVV24,Ultragenyx:Pediatric Study Shows Reduction In Bone Disease&improvement In Growth,2016-09-19 10:51:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/uTK6G0JX5kY/ultragenyxpediatric-study-shows-reduction-in-bone-diseaseimprovement-in-growth-20160919-00552,Ultragenyx:Pediatric Study Shows Reduction In Bone Disease&improvement In Growth
RARE,RARE:UW,BBG005KLVV24,Ultragenyx Reports Positive Interim Data from Phase 2 Study of KRN23 for the Treatment of Tumor-Induced Osteomalacia,2016-09-18 15:38:01 +0000,http://www.publicnow.com/view/819E45C9ED2671EBF21CCD3613DB2D4CF2759692,"[at noodls] - NOVATO, Calif., Sept. 18, 2016 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, ..."
RARE,RARE:UW,BBG005KLVV24,Ultragenyx to Host Conference Call to Discuss KRN23 Data Presented at ASBMR 2016 Annual Meeting,2016-09-16 12:48:02 +0000,http://www.publicnow.com/view/B0A310E3CE8B1677A4B1518B2E922607C362ED20,"[at noodls] - NOVATO, Calif., Sept. 16, 2016 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, ..."
RARE,RARE:UW,BBG005KLVV24,"Bevy Of Biotech Stocks Healthy; Sarepta, Bluebird, Exelixis Soar",2016-09-14 20:27:26 +0000,http://www.investors.com/research/ibd-industry-themes/bevy-of-biotech-stocks-healthy-sarepta-bluebird-exelixis-soar/,"Bevy Of Biotech Stocks Healthy; Sarepta, Bluebird, Exelixis Soar"
RARE,RARE:UW,BBG005KLVV24,Peek Under The Hood: IYH Has 14% Upside,2016-09-13 13:48:40 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/JfUS_XoFc2E/peek-under-the-hood-iyh-has-14-upside-cm678486,Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel we have compared the trading price of each holding against the average analyst 12 month forward target price and computed the weighted average implied analyst target price for the ETF itself For the
RARE,RARE:UW,BBG005KLVV24,Ultragenyx Pharmaceutical To Participate In Baird Global Conference At 10:15 AM,2016-09-08 09:15:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/LdB65CPtSzY/ultragenyx-pharmaceutical-to-participate-in-baird-global-conference-at-1015-am-20160908-00631,Ultragenyx Pharmaceutical To Participate In Baird Global Conference At 10:15 AM
RARE,RARE:UW,BBG005KLVV24,Discretionary Stocks Boost the Wells Fargo Growth Fund in YTD 2016,2016-09-01 14:05:07 +0000,http://marketrealist.com/2016/09/discretionary-stocks-boost-wells-fargo-growth-fund-ytd-2016/?utm_source=yahoo&utm_medium=feed,Discretionary Stocks Boost the Wells Fargo Growth Fund in YTD 2016
RARE,RARE:UW,BBG005KLVV24,Ultragenyx to Present at Baird 2016 Global Healthcare Conference,2016-09-01 12:30:00 +0000,http://finance.yahoo.com/news/ultragenyx-present-baird-2016-global-123000773.html,"[GlobeNewswire] - NOVATO, Calif., Sept. 01, 2016-- Ultragenyx Pharmaceutical Inc., a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced that Shalini ..."
RARE,RARE:UW,BBG005KLVV24,Ultragenyx Announces KRN23 Data Presentations at ASBMR 2016 Annual Meeting,2016-08-23 12:48:02 +0000,http://www.publicnow.com/view/DD481DF232729708F6953D20ADF8AECB82C05892,"[at noodls] - NOVATO, Calif., Aug. 23, 2016 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, ..."
RARE,RARE:UW,BBG005KLVV24,"After Medivation, These 6 Biotech Stocks Could Be M&A Targets Next",2016-08-22 18:57:00 +0000,http://blogs.barrons.com/stockstowatchtoday/2016/08/22/after-medivation-these-6-biotech-stocks-could-be-ma-targets-next/?mod=yahoobarrons&ru=yahoo,"After Medivation, These 6 Biotech Stocks Could Be M&A Targets Next"
RARE,RARE:UW,BBG005KLVV24,Ultragenyx Pharmaceutical To Participate In Wedbush PacGrow Conference At 9:45AM,2016-08-16 08:45:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/2ZbPh_nqqnA/ultragenyx-pharmaceutical-to-participate-in-wedbush-pacgrow-conference-at-945am-20160816-00387,Ultragenyx Pharmaceutical To Participate In Wedbush PacGrow Conference At 9:45AM
RARE,RARE:UW,BBG005KLVV24,"ULTRAGENYX PHARMACEUTICAL INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits",2016-08-12 21:16:56 +0000,http://biz.yahoo.com/e/160812/rare8-k.html,"ULTRAGENYX PHARMACEUTICAL INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits"
RARE,RARE:UW,BBG005KLVV24,Ultragenyx Pharmaceutical To Participate In Canaccord Conference At 11:30 AM ET,2016-08-10 10:30:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/S0vjdhGh8ic/ultragenyx-pharmaceutical-to-participate-in-canaccord-conference-at-1130-am-et-20160810-00630,Ultragenyx Pharmaceutical To Participate In Canaccord Conference At 11:30 AM ET
RARE,RARE:UW,BBG005KLVV24,Ultragenyx to Present at Upcoming Investor Conferences,2016-08-09 13:00:09 +0000,http://www.publicnow.com/view/3DC9E4E389791DEA3F51932271CE0ED62B50F7C7,"[at noodls] - NOVATO, Calif., Aug. 09, 2016 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, ..."
RARE,RARE:UW,BBG005KLVV24,"ULTRAGENYX PHARMACEUTICAL INC. Files SEC form 10-Q, Quarterly Report",2016-08-09 10:10:43 +0000,http://biz.yahoo.com/e/160809/rare10-q.html,"ULTRAGENYX PHARMACEUTICAL INC. Files SEC form 10-Q, Quarterly Report"
RARE,RARE:UW,BBG005KLVV24,Edited Transcript of RARE earnings conference call or presentation 8-Aug-16 9:00pm GMT,2016-08-09 02:27:29 +0000,http://finance.yahoo.com/news/edited-transcript-rare-earnings-conference-022729292.html,Edited Transcript of RARE earnings conference call or presentation 8-Aug-16 9:00pm GMT
RARE,RARE:UW,BBG005KLVV24,Ultragenyx reports 2Q loss,2016-08-08 20:57:28 +0000,http://sg.finance.yahoo.com/news/ultragenyx-reports-2q-loss-205728203.html,Ultragenyx reports 2Q loss
RARE,RARE:UW,BBG005KLVV24,Ultragenyx Reports Second Quarter 2016 Financial Results and Corporate Update,2016-08-08 20:28:18 +0000,http://www.publicnow.com/view/60A1227EAD8C6CC6CA731C30B0211E52EF124E83,"[at noodls] - NOVATO, Calif., Aug. 08, 2016 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, ..."
RARE,RARE:UW,BBG005KLVV24,"ULTRAGENYX PHARMACEUTICAL INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statement",2016-08-08 20:13:23 +0000,http://biz.yahoo.com/e/160808/rare8-k.html,"ULTRAGENYX PHARMACEUTICAL INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statement"
RARE,RARE:UW,BBG005KLVV24,Ultragenyx Pharmaceutical Q2 16 Earnings Conference Call At 5:00 PM ET,2016-08-08 15:00:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/SRQukdc9cB0/ultragenyx-pharmaceutical-q2-16-earnings-conference-call-at-500-pm-et-20160808-00773,Ultragenyx Pharmaceutical Q2 16 Earnings Conference Call At 5:00 PM ET
RARE,RARE:UW,BBG005KLVV24,MannKind Q2 16 Earnings Conference Call At 5:00 PM ET,2016-08-08 15:00:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Bxg9-lx0EOI/mannkind-q2-16-earnings-conference-call-at-500-pm-et-20160808-00774,MannKind Q2 16 Earnings Conference Call At 5:00 PM ET
RARE,RARE:UW,BBG005KLVV24,Q2 2016 Ultragenyx Pharmaceutical Inc Earnings Release - After Market Close,2016-08-08 11:07:03 +0000,http://biz.yahoo.com/research/earncal/20160808.html?t=rare,Q2 2016 Ultragenyx Pharmaceutical Inc Earnings Release - After Market Close
RARE,RARE:UW,BBG005KLVV24,9 Top Picks of Credit Suisse Still Have 50% Implied Upside — or Much More!,2016-08-06 13:15:23 +0000,http://247wallst.com/investing/2016/08/06/9-top-picks-of-credit-suisse-still-have-50-implied-upside-or-much-more/,9 Top Picks of Credit Suisse Still Have 50% Implied Upside — or Much More!
RARE,RARE:UW,BBG005KLVV24,5 Drug Stocks Reporting Q2 Earnings on Aug 8: AGN & More,2016-08-05 13:24:01 +0000,http://finance.yahoo.com/news/5-drug-stocks-reporting-q2-132401145.html,5 Drug Stocks Reporting Q2 Earnings on Aug 8: AGN & More
RARE,RARE:UW,BBG005KLVV24,"ULTRAGENYX PHARMACEUTICAL INC. Files SEC form 8-K, Other Events",2016-08-03 18:47:22 +0000,http://biz.yahoo.com/e/160803/rare8-k.html,"ULTRAGENYX PHARMACEUTICAL INC. Files SEC form 8-K, Other Events"
RARE,RARE:UW,BBG005KLVV24,Here’s What We’re Looking For From Ultragenyx Pharmaceutical Inc (RARE),2016-08-01 16:20:47 +0000,http://www.insidermonkey.com/blog/heres-what-were-looking-for-from-ultragenyx-pharmaceutical-inc-rare-467246/,Here’s What We’re Looking For From Ultragenyx Pharmaceutical Inc (RARE)
RARE,RARE:UW,BBG005KLVV24,Ultragenyx to Host Conference Call for Second Quarter 2016 Financial Results and Corporate Update,2016-08-01 12:41:03 +0000,http://www.publicnow.com/view/E8B6E46245300D5F7C43A91611CDB8795F07AC4A,"[at noodls] - NOVATO, Calif., Aug. 01, 2016 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, ..."
RARE,RARE:UW,BBG005KLVV24,Ultragenyx Announces Completion of Enrollment in Phase 3 Study of KRN23 in Adults with X-Linked Hypophosphatemia (XLH),2016-07-28 12:58:03 +0000,http://www.publicnow.com/view/2B11DAADF1F5F39312228D4BC239C0296DB36F27,"[at noodls] - NOVATO, Calif., July 28, 2016 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, ..."
RARE,RARE:UW,BBG005KLVV24,How Focusing On Obscure Diseases Made BioMarin A $15 Billion Company,2016-07-28 12:30:00 +0000,http://www.forbes.com/sites/matthewherper/2016/07/28/from-rare-to-great/?utm_source=yahoo&utm_medium=partner&utm_campaign=yahoofeed&partner=yahoomag,How Focusing On Obscure Diseases Made BioMarin A $15 Billion Company
RARE,RARE:UW,BBG005KLVV24,Ultragenyx Announces Completion of Enrollment in Phase 3 Study of Aceneuramic Acid Extended Release (Ace-ER) in GNE Myopathy,2016-07-27 12:38:01 +0000,http://www.publicnow.com/view/A2FC86DFDF0FCA0A0ACFA81CA8782F72DE22618B,"[at noodls] - NOVATO, Calif., July 27, 2016 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, ..."
RARE,RARE:UW,BBG005KLVV24,"Commit To Buy Ultragenyx Pharmaceutical At $40, Earn 12% Annualized Using Options",2016-07-26 17:22:51 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/NPYA5SPedHE/commit-to-buy-ultragenyx-pharmaceutical-at-40-earn-12-annualized-using-options-cm654999,"Investors eyeing a purchase of Ultragenyx Pharmaceutical Inc (Symbol RARE) shares, but tentative about paying the going market price of $56.40 share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract"
RARE,RARE:UW,BBG005KLVV24,These 5 Stocks Are Breaking Out This Summer,2016-07-26 11:59:00 +0000,https://www.thestreet.com/story/13651153/1/these-5-stocks-are-breaking-out-this-summer.html?puc=yahoo&cm_ven=YAHOO,These 5 Stocks Are Breaking Out This Summer
RARE,RARE:UW,BBG005KLVV24,Ultragenyx (RARE) Reports Positive Phase III rhGUS Data,2016-07-15 16:17:41 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/ZP6uS6yIv04/ultragenyx-rare-reports-positive-phase-iii-rhgus-data-cm649827,"Ultragenyx Pharmaceutical Inc.RARE announced positive top line data from a pivotal phase III study on recombinant human beta glucuronidase (rhGUS) for the treatment of mucopolysaccharidosis 7 (MPS 7), also known as Sly syndrome. The study assessed the safety and"
RARE,RARE:UW,BBG005KLVV24,Ultragenyx (RARE) Reports Positive Phase III rhGUS Data,2016-07-15 13:51:01 +0000,http://finance.yahoo.com/news/ultragenyx-rare-reports-positive-phase-135101364.html,Ultragenyx (RARE) Reports Positive Phase III rhGUS Data
RARE,RARE:UW,BBG005KLVV24,Ultragenyx's Final Stage Study Of Recombinant Human Beta-Glucuronidase Meets Primary Endpoint,2016-07-15 11:52:21 +0000,http://finance.yahoo.com/news/ultragenyxs-final-stage-study-recombinant-115221772.html,Ultragenyx's Final Stage Study Of Recombinant Human Beta-Glucuronidase Meets Primary Endpoint
RARE,RARE:UW,BBG005KLVV24,"3 Stocks to Watch on Thursday: Monsanto Company (MON), Ultragenyx Pharmaceutical Inc (RARE) and Yum! Brands, Inc. (YUM)",2016-07-15 11:14:25 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/iAlHF6m7EBM/3-stocks-to-watch-on-thursday-monsanto-company-mon-ultragenyx-pharmaceutical-inc-rare-and-yum-brands-inc-yum-cm649402,"As oil prices fell 4.4%, two major indexes continue to reach new heights, including the  S&P 500  which rose 0.01% Wednesday. The  Dow Jones Industrial"
RARE,RARE:UW,BBG005KLVV24,U.S. Hot Stocks: Hot Stocks to Watch,2016-07-15 09:38:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/dYR7Jf00iH4/us-hot-stocks-hot-stocks-to-watch-20160715-00362,U.S. Hot Stocks: Hot Stocks to Watch
RARE,RARE:UW,BBG005KLVV24,"Watch Out For BCLI, RARE''s Phase 3 Trial Hits Goal, JUNO Opens Wallet",2016-07-15 00:20:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/kDlnww1MR4w/watch-out-for-bcli-rares-phase-3-trial-hits-goal-juno-opens-wallet-20160715-00004,"Watch Out For BCLI, RARE''s Phase 3 Trial Hits Goal, JUNO Opens Wallet"
RARE,RARE:UW,BBG005KLVV24,Ultragenyx shares rise on metabolic drug study results,2016-07-14 20:34:49 +0000,http://www.marketwatch.com/News/Story/Story.aspx?guid=28614281-90F5-45CB-BA41-BFACBC0411F1&siteid=yhoof2,Ultragenyx shares rise on metabolic drug study results
RARE,RARE:UW,BBG005KLVV24,Ultragenyx Announces Positive Topline Data from Phase 3 Study of Recombinant Human Beta-Glucuronidase in Mucopolysaccharidosis Type 7,2016-07-14 20:18:08 +0000,http://www.publicnow.com/view/29BE85A2A04840675953CB3A4BEF74F6022B0FB8,"[at noodls] - Study meets primary endpoint of reduction in urinary GAG excretion and provides evidence of clinical improvement Company to host conference call today at 5pm ET to discuss results NOVATO, Calif., July ..."
RARE,RARE:UW,BBG005KLVV24,"Health Care Sector Update for 07/14/2016: RARE,ARNA,RNVA",2016-07-14 17:26:03 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/kHHg-Y5c-ss/health-care-sector-update-for-07142016-rarearnarnva-cm649349,"Top Health Care Stocks JNJ +0.23% PFE +1.07% MRK +0.74% ABT +0.22% AMGN +1.19% Health care stocks were slightly higher Thursday, with the NYSE Health Care Index and shares of health care companies in the S&P 500 both rising"
RARE,RARE:UW,BBG005KLVV24,10 Biotech Stocks That Could Erupt Within Months,2016-07-01 23:49:17 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/g5fUuO3fMgs/10-biotech-stocks-that-could-erupt-within-months-cm644110,"It's time to flip the calendar to a new month, but a new quarter as well, resetting the psychological clock for investors. We're also entering a time of year that's"
RARE,RARE:UW,BBG005KLVV24,Ultragenyx Receives Breakthrough Therapy Designation for KRN23 in Pediatric Patients with X-Linked Hypophosphatemia,2016-06-28 12:41:03 +0000,http://www.publicnow.com/view/114A12E61667D463B4FC60F473351AB8AEA49F1E,"[at noodls] - NOVATO, Calif., June 28, 2016 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, ..."
RARE,RARE:UW,BBG005KLVV24,Ultragenyx Pharma Receives Breakthrough Therapy Designation For KRN23,2016-06-28 08:37:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/ikB5iBKndkg/ultragenyx-pharma-receives-breakthrough-therapy-designation-for-krn23-20160628-00422,Ultragenyx Pharma Receives Breakthrough Therapy Designation For KRN23
RARE,RARE:UW,BBG005KLVV24,"Ultragenyx Appoints Karah Parschauer as Executive Vice President, General Counsel",2016-06-20 13:29:05 +0000,http://www.publicnow.com/view/6E8F9AA1CE15E58ABE6C4844F3D94C43837C31A7,"[at noodls] - NOVATO, Calif., June 20, 2016 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, ..."
RARE,RARE:UW,BBG005KLVV24,"Friday's ETF Movers: OIH, XBI",2016-06-17 20:02:52 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/B-mBYbKi4X0/fridays-etf-movers-oih-xbi-cm637198,"In trading on Friday, the Oil Services ETF ( OIH ) is outperforming other ETFs, up about 2.5% on the day. Components of that ETF showing particular strength include shares of Carbo Ceramics ( CRR ), up about 8.1%"
RARE,RARE:UW,BBG005KLVV24,Ultragenyx Pharma. To Present At Goldman Sachs Conference; Webcast At 4:20 PM ET,2016-06-08 15:00:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/MWLAk9GpwSQ/ultragenyx-pharma-to-present-at-goldman-sachs-conference-webcast-at-420-pm-et-20160608-00861,Ultragenyx Pharma. To Present At Goldman Sachs Conference; Webcast At 4:20 PM ET
RARE,RARE:UW,BBG005KLVV24,Ultragenyx and Takeda enter into a Collaboration to Develop and Commercialize Therapies for Rare Genetic Diseases,2016-06-07 23:08:05 +0000,http://www.publicnow.com/view/8802ADB5BBE2A5FFCB5F0AAE1ECE46D7E31A73A1,"[at noodls] - Ultragenyx to license and develop one or more product candidates from Takeda Takeda to make equity investment in Ultragenyx to fund development NOVATO, CA, June 7, 2016 and OSAKA, JAPAN, June 8, 2016- ..."
RARE,RARE:UW,BBG005KLVV24,Ultragenyx Pharmaceutical To Participate In Jefferies Conference At 11:00 AM ET,2016-06-07 10:00:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/O8L0lQbLoCg/ultragenyx-pharmaceutical-to-participate-in-jefferies-conference-at-1100-am-et-20160607-00691,Ultragenyx Pharmaceutical To Participate In Jefferies Conference At 11:00 AM ET
RARE,RARE:UW,BBG005KLVV24,Ultragenyx To License Product Candidates From Takeda; Takeda To Invest In RARE,2016-06-07 07:18:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/ycgpq_mWplc/ultragenyx-to-license-product-candidates-from-takeda-takeda-to-invest-in-rare-20160607-00273,Ultragenyx To License Product Candidates From Takeda; Takeda To Invest In RARE
RARE,RARE:UW,BBG005KLVV24,Ultragenyx Pharmaceutical (RARE) Jumps: Stock Up 6.6%,2016-06-01 15:14:07 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/ZJUE0k4sNXU/ultragenyx-pharmaceutical-rare-jumps-stock-up-66-cm628948,"Ultragenyx Pharmaceutical Inc.RARE was a big mover last session, as the company saw its shares rise over 6% on the day. The move came on solid volume too with far more shares changing hands than in a normal session."
RARE,RARE:UW,BBG005KLVV24,How The Parts Add Up: IYY Headed For $115,2016-05-31 14:06:15 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/JYBEflKmfL8/how-the-parts-add-up-iyy-headed-for-115-cm628228,"Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel , we have compared the trading price of each holding against the average analyst 12 month forward target price, and computed the weighted average"
RARE,RARE:UW,BBG005KLVV24,Ultragenyx Reports First Quarter 2016 Financial Results and Corporate Update,2016-05-09 20:38:22 +0000,http://www.publicnow.com/view/9A2BE05DDBD8A9729119105C5F08B4129AF993AA,"[at noodls] - NOVATO, Calif., May 09, 2016 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, ..."
RARE,RARE:UW,BBG005KLVV24,Ultragenyx reports 1Q loss,2016-05-09 20:25:35 +0000,http://sg.finance.yahoo.com/news/ultragenyx-reports-1q-loss-202535575.html,Ultragenyx reports 1Q loss
RARE,RARE:UW,BBG005KLVV24,"After-Hours Earnings Report for May 9, 2016 :  IFF, OPK, VVC, DNB, JUNO, BKD, TMH, SWX, RAX, LC, CVG, RARE",2016-05-09 19:02:53 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/jXiSc9Elkx4/after-hours-earnings-report-for-may-9-2016-iff-opk-vvc-dnb-juno-bkd-tmh-swx-rax-lc-cvg-rare-cm618407,"The following companies are expected to report earnings after hours on 05 09 2016. Visit our Earnings Calendar for a full list of expected earnings releases.  Internationa Flavors & Fragrances, Inc. ( IFF ) is reporting"
RARE,RARE:UW,BBG005KLVV24,Ultragenyx to Present at Bank of America Merrill Lynch Healthcare Conference,2016-05-06 12:44:08 +0000,http://www.publicnow.com/view/E4C48FF7626A645DD0CD3053DC600FA8545B0BF4,"[at noodls] - NOVATO, Calif., May 06, 2016 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, ..."
RARE,RARE:UW,BBG005KLVV24,Ultragenyx to Host Conference Call for First Quarter 2016 Financial Results and Corporate Update,2016-04-29 12:53:46 +0000,http://www.publicnow.com/view/6F406B4F6D2EFB712B47B309FEDBBB643FD2EECA,"[at noodls] - NOVATO, Calif., April 29, 2016 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, ..."
RARE,RARE:UW,BBG005KLVV24,Ultragenyx Reports Positive Interim Data from Phase 2 Study of KRN23 for the Treatment of Tumor-Induced Osteomalacia,2016-04-21 12:44:15 +0000,http://www.publicnow.com/view/C38BBE57796AFF102AB143F52D6A57E49EDB8491,"[at noodls] - NOVATO, Calif., April 21, 2016 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, ..."
RARE,RARE:UW,BBG005KLVV24,Ultragenyx and Saint Louis University's Center for World Health and Medicine Announce Research Collaboration to Advance Muscular Dystrophy Treatment,2016-03-23 12:58:49 +0000,http://www.publicnow.com/view/ECB861F3DB901FAC6B5852C0DECA3DA10AFF3BC7,"[at noodls] - NOVATO, Calif., March 23, 2016 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, ..."
RARE,RARE:UW,BBG005KLVV24,"Ultragenyx Appoints Lars Ekman, M.D., Ph.D., to Board of Directors",2016-03-21 12:59:06 +0000,http://www.publicnow.com/view/0D2AADF2C70228CB296F3CB7FFA8E687FA8317DF,"[at noodls] - NOVATO, Calif., March 21, 2016 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, ..."
RARE,RARE:UW,BBG005KLVV24,How The Parts Add Up: IYY Targets $114,2016-03-15 13:40:28 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/HEL3NV7wlxQ/how-the-parts-add-up-iyy-targets-114-cm593110,"Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel , we have compared the trading price of each holding against the average analyst 12 month forward target price, and computed the weighted average"
RARE,RARE:UW,BBG005KLVV24,Ultragenyx reports 4Q loss,2016-02-26 00:06:06 +0000,http://sg.finance.yahoo.com/news/ultragenyx-reports-4q-loss-000606881.html,Ultragenyx reports 4Q loss
RARE,RARE:UW,BBG005KLVV24,"Wednesday Sector Laggards: Biotechnology, Drugs",2016-02-03 20:14:21 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/HWjTQc_H2TM/wednesday-sector-laggards-biotechnology-drugs-cm574411,"In trading on Wednesday, biotechnology shares were relative laggards, down on the day by about 2.4%. Helping drag down the group were shares of Fate Therapeutics ( FATE ), off about 12.2% and shares of Vascular Biogenics ( VBLT"
RARE,RARE:UW,BBG005KLVV24,"Wednesday's ETF Movers: GDX, XBI",2016-02-03 20:13:46 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/uy8zhBLcoGw/wednesdays-etf-movers-gdx-xbi-cm574407,"In trading on Wednesday, the Gold Miners ETF ( GDX ) is outperforming other ETFs, up about 5.5% on the day. Components of that ETF showing particular strength include shares of Yamana Gold ( AUY ), up about 11.1%"
RARE,RARE:UW,BBG005KLVV24,Interesting RARE Put And Call Options For March 18th,2016-01-22 18:23:15 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/AdPWpJjU_gY/interesting-rare-put-and-call-options-for-march-18th-cm569115,"Investors in Ultragenyx Pharmaceutical Inc (Symbol RARE) saw new options become available this week, for the March 18th expiration. At Stock Options Channel , our YieldBoost formula has looked up and down the RARE options chain for the new"
RARE,RARE:UW,BBG005KLVV24,Tuesday's ETF with Unusual Volume: FPX,2016-01-19 21:11:45 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/A7c3DGCZmSc/tuesdays-etf-with-unusual-volume-fpx-cm567581,"The First Trust US IPO Index Fund ETF ( FPX ) is seeing unusually high volume in afternoon trading Tuesday, with over 740,000 shares traded versus three month average volume of about 101,000. Shares of FPX were down about"
RARE,RARE:UW,BBG005KLVV24,Ultragenyx to Present at the J.P. Morgan Healthcare Conference,2016-01-05 13:49:01 +0000,http://www.noodls.com/view/E5060EA4BEC70C4451714DF0C82E2B3925B15D4F,"[at noodls] - NOVATO, Calif., Jan. 05, 2016 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, ..."
RARE,RARE:UW,BBG005KLVV24,Ultragenyx reports 3Q loss,2015-11-10 00:07:57 +0000,http://sg.finance.yahoo.com/news/ultragenyx-reports-3q-loss-000757007.html,Ultragenyx reports 3Q loss
RARE,RARE:UW,BBG005KLVV24,Ultragenyx Reports Third Quarter 2015 Financial Results and Corporate Update,2015-11-09 21:36:05 +0000,http://www.noodls.com/view/FF8E4464EF3310954A7B3CE2CF3CA3F8935770C7,[at noodls] - Ultragenyx Reports Third Quarter 2015 Financial Results and Corporate Update
RARE,RARE:UW,BBG005KLVV24,"Amid Alibaba fever, reasons for caution in IPO market",2014-09-11 17:09:19 +0000,http://sg.finance.yahoo.com/news/amid-alibaba-fever-reasons-caution-170919488.html,"Amid Alibaba fever, reasons for caution in IPO market"
